



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :		A1	(11) International Publication Number: WO 97/08145
C07D 213/55, A61K 31/44, C07C 279/18, A61K 31/155, 31/36, C07D 405/10, A61K 31/395, C07D 223/12, 401/14, 207/16, C07C 275/28, A61K 31/17, C07D 401/10, 317/30			(43) International Publication Date: 6 March 1997 (06.03.97)
(21) International Application Number: PCT/US96/13500		Bipinchandra, Nanubhai [US/US]; 200 Annapolis Drive, Vernon Hills, IL 60060 (US). LINDMARK, Richard, John [US/US]; 1165 Rue La Ville, St. Louis, MI 63141 (US). RICO, Joseph, Gerace [US/US]; 524 Weatherby Terrace Drive, Ballwin, MI 63021 (US). ROGERS, Thomas, Edward [US/US]; 755 Trago Creek Drive, Ballwin, MI 63021 (US). RUSSELL, Mark, Andrew [GB/US]; 475 Cross Road, Gurnee, IL 60031 (US).	
(22) International Filing Date: 27 August 1996 (27.08.96)		(74) Agents: KOVACEVIC, Cynthia, S. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).	
(30) Priority Data: 60/003,277 30 August 1995 (30.08.95) US		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(60) Parent Application or Grant (63) Related by Continuation US 60/003,277 (CON) Filed on 30 August 1995 (30.08.95)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only): RUMINSKI, Peter, Gerard [US/US]; 391 Crestbury, Ballwin, MI 63011 (US). CLARE, Michael [GB/US]; 5154 West Brown Street, Skokie, IL 60077 (US). COLLINS, Paul, Waddell [US/US]; 1557 Hawthorne Place, Deerfield, IL 60015 (US). DESAI,	
(54) Title: META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS			
(57) Abstract			
<p>The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein A is (a) or (b) or (c) or (d) pharmaceutical compositions thereof and methods of using such compounds and compositions as $\alpha_v\beta_3$ integrin antagonists.</p>			
<p style="text-align: right;">(I)</p>			
<p style="text-align: center;">(a)</p>			
<p style="text-align: center;">(b)</p>			
<p style="text-align: center;">(c)</p>			
<p style="text-align: center;">(d)</p>			

PCT/US01/50619

WEST

META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS
INTEGRIN ANTAGONISTS

The present application claims priority under 35
5 USC §119(e) of United States provisional application
Serial No. 60/003,277 filed August 30, 1995.

Field of the Invention

The present invention relates to pharmaceutical
10 agents (compounds) which are useful as α,β , integrin
antagonists and as such are useful in pharmaceutical
compositions and in methods for treating conditions
mediated by α,β , by inhibiting or antagonizing α,β ,
integrins.

15

Background of the Invention

Integrins are a group of cell surface
glycoproteins which mediate cell adhesion and therefore
are useful mediators of cell adhesion interactions
20 which occur during various biological processes.
Integrins are heterodimers composed of noncovalently
linked α and β polypeptide subunits. Currently eleven
different α subunits have been identified and six
different β subunits have been identified. The various
25 α subunits can combine with various β subunits to form
distinct integrins.

The integrin identified as α,β , (also known as the
vitronectin receptor) has been identified as an
integrin which plays a role in various conditions or
30 disease states including tumor metastasis, solid tumor
growth (neoplasia), osteoporosis, Paget's disease,
humoral hypercalcemia of malignancy, angiogenesis,
including tumor angiogenesis, retinopathy, arthritis,
including rheumatoid arthritis, periodontal disease,
35 psoriasis and smooth muscle cell migration (e.g.
restenosis). Additionally, it has been found that such
agents would be useful as antivirals, antifungals and
antimicrobials. Thus, compounds which selectively

- 2 -

inhibit or antagonize α,β , would be beneficial for treating such conditions.

It has been shown that the α,β , integrin and other α , containing integrins bind to a number of Arg-Gly-Asp (RGD) containing matrix macromolecules. Compounds containing the RGD sequence mimic extracellular matrix ligands so as to bind to cell surface receptors.

5 However, it is also known that RGD peptides in general are non-selective for RGD dependent integrins. For example, most RGD peptides which bind to α,β , also bind to α,β_3 , α,β_1 and α_m,β . Antagonism of platelet α_m,β , (also known as the fibrinogen receptor) is known to block platelet aggregation in humans. In order to avoid bleeding side-effects when treating the conditions or 10 disease states associated with the integrin α,β , it would be beneficial to develop compounds which are 15 selective antagonists of α,β , as opposed to α_m,β .

Tumor cell invasion occurs by a three step process: 1) tumor cell attachment to extracellular 20 matrix; 2) proteolytic dissolution of the matrix; and 3) movement of the cells through the dissolved barrier. This process can occur repeatedly and can result in metastases at sites distant from the original tumor.

Seftor et al. (Proc. Natl. Acad. Sci. USA, Vol. 89 25 (1992) 1557-1561) have shown that the α,β , integrin has a biological function in melanoma cell invasion.

Montgomery et al., (Proc. Natl. Acad. Sci. USA, Vol. 91 30 (1994) 8856-60) have demonstrated that the integrin α,β , expressed on human melanoma cells promotes a survival signal, protecting the cells from apoptosis. Mediation of the tumor cell metastatic pathway by interference with the α,β , integrin cell adhesion receptor to impede tumor metastasis would be beneficial.

35 Brooks et al. (Cell, Vol. 79 (1994) 1157-1164) have demonstrated that antagonists of α,β , provide a therapeutic approach for the treatment of neoplasia (inhibition of solid tumor growth) since systemic

- 3 -

administration of $\alpha,\beta,$ antagonists causes dramatic regression of various histologically distinct human tumors.

The adhesion receptor integrin $\alpha,\beta,$ was identified 5 as a marker of angiogenic blood vessels in chick and man and therefore such receptor plays a critical role in angiogenesis or neovascularization. Angiogenesis is characterized by the invasion, migration and proliferation of smooth muscle and endothelial cells. 10 Antagonists of $\alpha,\beta,$ inhibit this process by selectively promoting apoptosis of cells in neovasculature. The growth of new blood vessels, or angiogenesis, also contributes to pathological conditions such as diabetic retinopathy (Adonis et al., Amer. J. Ophthal., Vol. 15 118, (1994) 445-450) and rheumatoid arthritis (Peacock et al., J. Exp. Med., Vol. 175, (1992), 1135-1138). Therefore, $\alpha,\beta,$ antagonists would be useful therapeutic targets for treating such conditions associated with neovascularization (Brooks et al., Science, Vol. 264, 20 (1994), 569-571).

It has been reported that the cell surface receptor $\alpha,\beta,$ is the major integrin on osteoclasts responsible for attachment to bone. Osteoclasts cause bone resorption and when such bone resorbing activity 25 exceeds bone forming activity it results in osteoporosis (a loss of bone), which leads to an increased number of bone fractures, incapacitation and increased mortality. Antagonists of $\alpha,\beta,$ have been shown to be potent inhibitors of osteoclastic activity 30 both in vitro [Sato et al., J. Cell. Biol., Vol. 111 (1990) 1713-1723] and in vivo [Fisher et al., Endocrinology, Vol. 132 (1993) 1411-1413]. Antagonism of $\alpha,\beta,$ leads to decreased bone resorption and therefore restores a normal balance of bone forming and resorbing 35 activity. Thus it would be beneficial to provide antagonists of osteoclast $\alpha,\beta,$ which are effective inhibitors of bone resorption and therefore are useful in the treatment or prevention of osteoporosis.


- 4 -

The role of the α,β , integrin in smooth muscle cell migration also makes it a therapeutic target for prevention or inhibition of neointimal hyperplasia which is a leading cause of restenosis after vascular 5 procedures (Choi et al., J. Vasc. Surg. Vol. 19(1) (1994) 125-34). Prevention or inhibition of neointimal hyperplasia by pharmaceutical agents to prevent or inhibit restenosis would be beneficial.

White (Current Biology, Vol. 3(9)(1993) 596-599) 10 has reported that adenovirus uses α,β , for entering host cells. The integrin appears to be required for endocytosis of the virus particle and may be required for penetration of the viral genome into the host cell cytoplasm. Thus compounds which inhibit α,β , would find 15 usefulness as antiviral agents.

Summary of the Invention


The present invention relates to a class of compounds represented by the Formula I



or a pharmaceutically acceptable salt thereof, wherein

30

A is



35

- 5 -

wherein Y¹ is selected from the group consisting of N-R², O, and S;

R² is selected from the group consisting of H;
5 alkyl; aryl; hydroxy; alkoxy; cyano; nitro; amino; alkenyl; alkynyl; amido; alkylcarbonyl; arylcarbonyl; alkoxy carbonyl; aryloxycarbonyl; haloalkylcarbonyl; haloalkoxycarbonyl; alkylthiocarbonyl; arylthiocarbonyl; acyloxymethoxycarbonyl; alkyl optionally substituted with one or more substituent selected from lower alkyl, halogen, hydroxyl, haloalkyl, cyano, nitro, carboxyl, amino, alkoxy, aryl or aryl optionally substituted with one or more halogen, haloalkyl, lower alkyl, alkoxy, cyano, 15 alkylsulfonyl, alkylthio, nitro, carboxyl, amino, hydroxyl, sulfonic acid, sulfonamide, aryl, fused aryl, monocyclic heterocycles, or fused monocyclic heterocycles; aryl optionally substituted with one 20 or more substituent selected from halogen, haloalkyl, hydroxy, lower alkyl, alkoxy, methylenedioxy, ethylenedioxy, cyano, nitro, alkylthio, alkylsulfonyl, sulfonic acid, sulfonamide, carboxyl derivatives, amino, aryl, fused aryl, monocyclic heterocycles and fused 25 monocyclic heterocycle; monocyclic heterocycles; and monocyclic heterocycles optionally substituted with one or more substituent selected from halogen, haloalkyl, lower alkyl, alkoxy, amino, nitro, hydroxy, carboxyl derivatives, cyano, alkylthio, alkylsulfonyl, sulfonic acid, sulfonamide, aryl or fused aryl; or 30 R² taken together with R⁷ forms a 4-12 membered dinitrogen containing heterocycle optionally substituted with one or more substituent selected from the group consisting of lower alkyl, hydroxy, 35

- 6 -

keto, alkoxy, halo, phenyl, amino, carboxyl or carboxyl ester, and fused phenyl;


5 or R² taken together with R⁷ forms a 5 membered heteroaromatic ring optionally substituted with one or more substituent selected from lower alkyl, phenyl and hydroxy;

10 or R² taken together with R⁷ forms a 5 membered heteroaromatic ring fused with a phenyl group;

15 R⁷ (when not taken together with R²) and R⁸ are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; aralkyl; amino; alkylamino; hydroxy; alkoxy; arylamino; amido, alkylcarbonyl, arylcarbonyl; alkoxycarbonyl; aryloxy; aryloxycarbonyl; haloalkylcarbonyl; haloalkoxycarbonyl; alkylthiocarbonyl; arylthiocarbonyl; acyloxymethoxycarbonyl; cycloalkyl; bicycloalkyl; aryl; acyl; benzoyl; alkyl optionally substituted with one or more substituent selected from lower alkyl, halogen, hydroxy, haloalkyl, cyano, nitro, carboxyl derivatives, amino, alkoxy, thio, alkylthio, sulfonyl, aryl, aralkyl, aryl optionally substituted with one or more substituent selected from halogen, haloalkyl, lower alkyl, alkoxy, methylenedioxy, ethylenedioxy, alkylthio, haloalkylthio, thio, hydroxy, cyano, nitro, 20 carboxyl derivatives, aryloxy, amido, acylamino, amino, alkylamino, dialkylamino, trifluoroalkoxy, trifluoromethyl, sulfonyl, alkylsulfonyl, haloalkylsulfonyl, sulfonic acid, sulfonamide, aryl, fused aryl, monocyclic heterocycles, fused 25 monocyclic heterocycles; aryl optionally substituted with one or more substituent selected from halogen, haloalkyl, lower alkyl, alkoxy, 30 35

- 7 -

methylenedioxy, ethylenedioxy, alkylthio,
 haloalkylthio, thio, hydroxy, cyano, nitro,
 carboxyl derivatives, aryloxy, amido, acylamino,
 amino, alkylamino, dialkylamino, trifluoroalkoxy,
 5 trifluoromethylsulfonyl, alkylsulfonyl, sulfonic
 acid, sulfonamide, aryl, fused aryl, monocyclic
 heterocycles, or fused monocyclic heterocycles;
 monocyclic heterocycles; monocyclic heterocycles
 optionally substituted with one or more
 10 substituent selected from halogen, haloalkyl,
 lower alkyl, alkoxy, aryloxy, amino, nitro,
 hydroxy, carboxyl derivatives, cyano, alkylthio,
 alkylsulfonyl, aryl, fused aryl; monocyclic and
 15 bicyclic heterocyclicalkyls; $-\text{SO}_2\text{R}^{10}$ wherein R^{10} is
 selected from the group consisting of alkyl, aryl
 and monocyclic heterocycles, all optionally
 substituted with one or more substituent selected
 from the group consisting of halogen, haloalkyl,
 20 alkyl, alkoxy, cyano, nitro, amino, acylamino,
 trifluoroalkyl, amido, alkylaminosulfonyl,
 alkylsulfonyl, alkylsulfonylamino, alkylamino,
 dialkylamino, trifluoromethylthio,
 trifluoroalkoxy, trifluoromethylsulfonyl, aryl,
 25 aryloxy, thio, alkylthio, and monocyclic
 heterocycles; and



or NR^7 and R^8 taken together form a 4-12 membered
 mononitrogen containing monocyclic or bicyclic
 30 ring optionally substituted with one or more
 substituent selected from lower alkyl, carboxyl
 derivatives, aryl or hydroxy and wherein said ring
 optionally contains a heteroatom selected from the
 group consisting of O, N and S;


- 8 -

R⁵ is selected from the group consisting of H, alkyl, alkenyl, alkynyl, benzyl, and phenethyl;

or

5

A is



10

15

20

25

wherein Y² is selected from the group consisting of alkyl; cycloalkyl; bicycloalkyl; aryl; monocyclic heterocycles; alkyl optionally substituted with aryl which can also be optionally substituted with one or more substituent selected from halo, haloalkyl, alkyl, nitro, hydroxy, alkoxy, aryloxy, aryl, or fused aryl; aryl optionally substituted with one or more substituent selected from halo, haloalkyl, hydroxy, alkoxy, aryloxy, aryl, fused aryl, nitro, methylenedioxy, ethylenedioxy, or alkyl; alkynyl; alkenyl; -S-R⁹ and -O-R⁹ wherein R⁹ is selected from the group consisting of H; alkyl; aralkyl; aryl; alkenyl; and alkynyl; or R⁹ taken together with R⁷ forms a 4-12 membered mononitrogen and monosulfur or monooxygen containing heterocyclic ring optionally substituted with lower alkyl, hydroxy, keto, phenyl, carboxyl or carboxyl ester, and fused phenyl; or R⁹ taken together with R⁷ is thiazole; oxazole; benzoxazole; or benzothiazole; and

R⁵ and R⁷ are as defined above;


30

or Y² (when Y² is carbon) taken together with R⁷ forms a 4-12 membered mononitrogen or dinitrogen containing ring optionally substituted with alkyl, aryl, keto or hydroxy;

- 9 -

or A is

5




where R² and R⁷ taken together form a 5-8 membered dinitrogen containing heterocycle optionally substituted with one or more substituent selected from the group consisting of lower alkyl, hydroxy, keto, phenyl, or carboxyl derivatives; and R⁸ is selected from the group consisting of alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, or acyloxymethoxycarbonyl; and

10 15 20 25 30 35 R⁵ is defined as above

or A is

25



where R² and R⁷ taken together form a 5-8 membered dinitrogen containing heterocycle optionally substituted with hydroxy, keto, phenyl, or alkyl; and

30

35

R⁸ are both selected from the group consisting of alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl and acyloxymethoxycarbonyl;

- 10 -

5 Z^1 is one or more substituent selected from the group consisting of H; alkyl; hydroxy; alkoxy; aryloxy; halogen; haloalkyl; haloalkoxy; nitro; amino; alkylamino; acylamino; dialkylamino; cyano; alkylthio; alkylsulfonyl; carboxyl derivatives; trihaloacetamide; acetamide; aryl; fused aryl; cycloalkyl; thio; monocyclic heterocycles; fused monocyclic heterocycles; and A, wherein A is defined above;

10

V is selected from the group consisting of $-N-(R^6)-$ wherein R^6 is selected from the group consisting of H; lower alkyl; cycloalkyl; aralkyl; aryl; and monocyclic heterocycles; or R^6 taken together with Y, forms a 4-12 membered mononitrogen containing ring;

15

20 Y, Y^3 , Z and Z^3 are independently selected from the group consisting of hydrogen; alkyl; aryl; and cycloalkyl; or Y and Z taken together form a cycloalkyl; or Y^3 and Z^3 taken together form a cycloalkyl;

25 n is an integer 1, 2, or 3;

30

t is an integer 0, 1, or 2;

35 p is an integer 0, 1, 2, or 3;

30 R is $X-R^3$ wherein X is selected from the group consisting of O, S and NR^4 , wherein R^3 and R^4 are independently selected from the group consisting of hydrogen; alkyl; alkenyl; alkynyl; haloalkyl; aryl; arylalkyl; sugars; steroids; polyalkylethers; alkylamido; alkyl N,N -dialkylamido; pivaloyloxymethyl; and in the case


- 11 -

of the free acid, all pharmaceutically acceptable salts thereof;

5 R¹ is selected from the group consisting of hydrogen; alkyl; alkenyl; alkynyl; aryl; carboxyl derivatives; haloalkyl; cycloalkyl; monocyclic heterocycles; monocyclic heterocycles optionally substituted with alkyl, halogen, haloalkyl, cyano, hydroxy, aryl, fused aryl, nitro, alkoxy, aryloxy, 10 alkylsulfonyl, arylsulfonyl, sulfonamide, thio, alkylthio, carboxyl derivatives, amino, amido; alkyl optionally substituted with one or more of halo, haloalkyl, hydroxy, alkoxy, aryloxy, thio, 15 alkylthio, alkynyl, alkenyl, alkyl, arylthio, alkylsulfoxide, alkylsulfonyl, arylsulfoxide, arylsulfonyl, cyano, nitro, amino, alkylamino, dialkylamino, alkylsulfonamide, arylsulfonamide, acylamide, carboxyl derivatives, sulfonamide, 20 sulfonic acid, phosphonic acid derivatives, phosphinic acid derivatives, aryl, arylthio, arylsulfoxide, or arylsulfone all optionally substituted on the aryl ring with halo, alkyl, haloalkyl, cyano, nitro, hydroxy, carboxyl derivatives, alkoxy, aryloxy, amino, alkylamino, 25 dialkylamino, amido, aryl, fused aryl, monocyclic heterocycles; and fused monocyclic heterocycles, monocyclic heterocyclic thio, monocyclic heterocyclicsulfoxide, and monocyclic heterocyclic sulfone, which can be optionally substituted with halo, haloalkyl, nitro, hydroxy, alkoxy, fused aryl, or alkyl; 30 alkylcarbonyl, haloalkylcarbonyl, and arylcarbonyl; 35

- 12 -

aryl optionally substituted in one or more positions with halo, haloalkyl, alkyl, alkoxy, aryloxy, methylenedioxy, ethylenedioxy, alkylthio, haloalkylthio, thio, hydroxy, cyano, nitro, 5 acyloxy, carboxyl derivatives, carboxyalkoxy; amido, acylamino, amino, alkylamino, dialkylamino, trifluoroalkoxy, trifluoromethylsulfonyl, alkylsulfonyl, sulfonic acid, sulfonamide, aryl, fused aryl, monocyclic heterocycles and fused 10 monocyclic heterocycles; and



and provided that taken together with the nitrogen, R⁷ and R⁸ comprise an amino acid;

15 and

20 R¹¹ is selected from the group consisting of H, alkyl, aralkyl, alkenyl, alkynyl, haloalkyl or haloalkynyl or R¹¹ taken together with Y forms a 4- 12 membered mononitrogen containing ring.

It is another object of the invention to provide pharmaceutical compositions comprising compounds of the Formula I. Such compounds and compositions are useful 25 in selectively inhibiting or antagonizing the α,β , integrin and therefore in another embodiment the present invention relates to a method of selectively inhibiting or antagonizing the α,β , integrin. The invention further involves treating or inhibiting 30 pathological conditions associated therewith such as osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, solid tumor growth (neoplasia), angiogenesis, including tumor


- 13 -

angiogenesis, retinopathy including diabetic
retinopathy, arthritis, including rheumatoid arthritis,
periodontal disease, psoriasis, smooth muscle cell
migration and restenosis in a mammal in need of such
5 treatment. Additionally, such pharmaceutical agents
are useful as antiviral agents, and antimicrobials.

Detailed Description


10 The present invention relates to a class of
compounds represented by the Formula I, described
above.

A preferred embodiment of the present invention is
a compound of the Formula II



wherein R⁵, R⁷ and R⁸ are independently selected from H,
alkyl, aryl, carboxyalkyl, substituted aryl,
25 substituted arylsulfonyl, and arylalkyl or NR⁷ and R⁸
taken together form a 4-12 membered mononitrogen
containing ring optionally substituted and the other
variables are as described in Formula I.


Another preferred embodiment of the present
30 invention is a compound of the Formula III



- 14 -


wherein Y^1 is $-NR^2$ and R^2 taken together with R^7 forms an optionally substituted 4-12 membered ring and the other variables are as defined above in Formula I.

5 Another preferred embodiment of the present invention is a compound of the Formula IV



15 wherein Y^2 taken together with R^7 forms a 4-12 membered ring and the other variables are as defined above in Formula I.

Another preferred embodiment of the present invention is a compound of the Formula V



wherein the variables are as defined above in Formula I.

30 The invention further relates to pharmaceutical compositions containing therapeutically effective amounts of the compounds of Formulas I-V.

35 The invention also relates to a method of selectively inhibiting or antagonizing the α,β , integrin and more specifically relates to a method of inhibiting bone resorption, periodontal disease, osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, solid tumor growth (neoplasia),

- 15 -

angiogenesis, including tumor angiogenesis, retinopathy including diabetic retinopathy, arthritis, including rheumatoid arthritis, smooth muscle cell migration and restenosis by administering a therapeutically effective 5 amount of a compound of the Formula I-V to achieve such inhibition together with a pharmaceutically acceptable carrier.

The following is a list of definitions of various terms used herein:

As used herein, the terms "alkyl" or "lower alkyl" refer to a straight chain or branched chain hydrocarbon radicals having from about 1 to about 10 carbon atoms, and more preferably 1 to about 6 carbon atoms.

5 Examples of such alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, neopentyl, hexyl, isoheptyl, and the like.

As used herein the terms "alkenyl" or "lower alkenyl" refer to unsaturated acyclic hydrocarbon radicals containing at least one double bond and 2 to about 6 carbon atoms, which carbon-carbon double bond may have either cis or trans geometry within the 10 alkenyl moiety, relative to groups substituted on the alkenyl double bond carbons. Examples of such groups are 15 ethenyl, propenyl, butenyl, isobut enyl, pentenyl, hexenyl and the like.

As used herein the terms "alkynyl" or "lower alkynyl" refer to acyclic hydrocarbon radicals 20 containing one or more triple bonds and 2 to about 6 carbon atoms. Examples of such groups are ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like.

The term "cycloalkyl" as used herein means 25 saturated or partially unsaturated cyclic carbon radicals containing 3 to about 8 carbon atoms and more preferably 4 to about 6 carbon atoms. Examples of such cycloalkyl radicals include cyclopropyl, cyclopropenyl,

- 16 -

cyclobutyl, cyclopentyl, cyclohexyl, 2-cyclohexen-1-yl, and the like.

The term "aryl" as used herein denotes aromatic ring systems composed of one or more aromatic rings.

5 Preferred aryl groups are those consisting of one, two or three aromatic rings. The term embraces aromatic radicals such as phenyl, pyridyl, naphthyl, thiophene, furan, biphenyl and the like.

As used herein, the term "cyano" is represented by

10 a radical of the formula ---CN .

The terms "hydroxy" and "hydroxyl" as used herein are synonymous and are represented by a radical of the formula ---OH .

15 The term "lower alkylene" or "alkylene" as used herein refers to divalent linear or branched saturated hydrocarbon radicals of 1 to about 6 carbon atoms.

20 As used herein the term "alkoxy" refers to straight or branched chain oxy containing radicals of the formula ---OR^2 , wherein R^2 is an alkyl group as defined above. Examples of alkoxy groups encompassed include methoxy, ethoxy, n-propoxy, n-butoxy, isopropoxy, isobutoxy, sec-butoxy, t-butoxy and the like.

25 As used herein the terms "arylalkyl" or "aralkyl" refer to a radical of the formula $\text{---R}^2\text{---R}^1$ wherein R^1 is aryl as defined above and R^2 is an alkylene as defined above. Examples of aralkyl groups include benzyl, pyridylmethyl, naphthylpropyl, phenethyl and the like.

30 As used herein the term "nitro" is represented by a radical of the formula ---NO_2 .

- 17 -

As used herein the term "halo" or "halogen" refers to bromo, chloro, fluoro or iodo.

As used herein the term "haloalkyl" refers to alkyl groups as defined above substituted with one or 5 more of the same or different halo groups at one or more carbon atom. Examples of haloalkyl groups include trifluoromethyl, dichloroethyl, fluoropropyl and the like.

As used herein the term "carboxyl" or "carboxy" 10 refers to a radical of the formula -COOH.

As used herein the term "carboxyl ester" refers to a radical of the formula -COOR²³ wherein R²³ is selected from the group consisting of H, alkyl, aralkyl or aryl as defined above.

15 As used herein the term "carboxyl derivative"

refers to a radical of the formula $\begin{array}{c} Y^6 \\ || \\ -C-Y^7R^{23} \end{array}$ wherein

Y⁶ and Y⁷ are independently selected from the group consisting of O, N or S and R²³ is selected from the group consisting of H, alkyl, aralkyl or aryl as 20 defined above.

As used herein the term "amino" is represented by a radical of the formula -NH₂.

As used herein the term "alkylsulfonyl" or "alkylsulfone" refers to a radical of the formula

25 $\begin{array}{c} O \\ || \\ -S-R^{24} \\ || \\ O \end{array}$ wherein R²⁴ is alkyl as defined above.

As used herein the term "alkylthio" refers to a radical of the formula -SR²⁴ wherein R²⁴ is alkyl as defined above.

- 18 -

As used herein the term "sulfonic acid" refers to

a radical of the formula $\begin{array}{c} \text{O} \\ \parallel \\ \text{S}-\text{OR}' \end{array}$ wherein R' is H,

alkyl or aryl as defined above.

As used herein the term "sulfonamide" refers to a

5 radical of the formula $\begin{array}{c} \text{O} \\ \parallel \\ \text{S}-\text{N}(\text{R}')\text{R}'' \end{array}$ wherein R' and R'' are as

defined above.


As used herein the term "fused aryl" refers to an aromatic ring such as the aryl groups defined above fused to one or more phenyl rings. Embraced by the 10 term "fused aryl" is the radical naphthyl.


As used herein the terms "monocyclic heterocycle" or "monocyclic heterocyclic" refer to a monocyclic ring containing from 4 to about 12 atoms, and more preferably from 5 to about 10 atoms, wherein 1 to 3 of 15 the atoms are heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur with the understanding that if two or more different heteroatoms are present at least one of the heteroatoms must be nitrogen. Representative of such monocyclic 20 heterocycles are imidazole, furan, pyridine, oxazole, pyran, triazole, thiophene, pyrazole, thiazole, thiadiazole, and the like.

As used herein the term "fused monocyclic heterocycle" refers to a monocyclic heterocycle as 25 defined above with a benzene fused thereto. Examples of such fused monocyclic heterocycles include benzofuran, benzopyran, benzodioxole, benzothiazole, benzothiophene, benzimidazole and the like.


- 19 -

As used herein the term "methylenedioxy" refers to

the radical  and the term "ethylenedioxy" refers



to the radical .

As used herein the term "4-12 membered dinitrogen containing heterocycle" refers to a radical of the

formula  wherein m is 1 or 2 and R¹⁹ is

H, alkyl, aryl, or aralkyl and more preferably refers to 4-9 membered ring and includes rings such as imidazoline.

As used herein the term "5-membered optionally substituted heteroaromatic ring" includes for example a


radical of the formula  or  and

"5-membered heteroaromatic ring fused with a phenyl" refers to such a "5-membered heteroaromatic ring" with a phenyl fused thereto. Representative of such 5-membered heteroaromatic rings fused with a phenyl is benzimidazole.

- 20 -


As used herein the term "bicycloalkyl" refers to a bicyclic hydrocarbon radical containing 6 to about 12 carbon atoms which is saturated or partially unsaturated.

5 As used herein the term "acyl" refers to a radical


of the formula  wherein R²⁶ is alkyl, alkenyl,

alkynyl, aryl or aralkyl and optionally substituted thereon as defined above. Encompassed by such radical are the groups acetyl, benzoyl and the like.

10 As used herein the term "thio" refers to a radical

of the formula .


As used herein the term "sulfonyl" refers to a

radical of the formula  wherein R²⁷ is alkyl,


aryl or aralkyl as defined above.

15

As used herein the term "haloalkylthio" refers to a radical of the formula -S-R²⁸ wherein R²⁸ is haloalkyl as defined above.

20 As used herein the term "aryloxy" refers to a radical of the formula  wherein R²⁹ is aryl as

defined above.


As used herein the term "acylamino" refers to a radical of the formula  wherein R³⁰ is alkyl,

aralkyl or aryl as defined above.

- 21 -

As used herein the term "amido" refers to a

radical of the formula



As used herein the term "alkylamino" refers to a radical of the formula $-\text{NHR}^{32}$ wherein R^{32} is alkyl as defined above.

As used herein the term "dialkylamino" refers to a radical of the formula $-\text{NR}^{33}\text{R}^{34}$ wherein R^{33} and R^{34} are the same or different alkyl groups as defined above.

As used herein the term "trifluoromethyl" refers to a radical of the formula $\begin{array}{c} \text{F} \\ | \\ \text{C}-\text{F} \\ | \\ \text{F} \end{array}$.

As used herein the term "trifluoroalkoxy" refers to a radical of the formula $\text{F}_3\text{C}-\text{R}^{35}-\text{O}-\begin{array}{c} \text{F} \\ | \\ \text{C} \end{array}$ wherein R^{35} is a bond or an alkylene as defined above.

As used herein the term "alkylaminosulfonyl" refers to a radical of the formula $\text{R}^{36}-\text{N}(\text{H})-\text{S}-\begin{array}{c} \text{O} \\ | \\ \text{C} \end{array}$ wherein

R^{36} is alkyl as defined above.

As used herein the term "alkylsulfonylamino"

refers to a radical of the formula $\text{R}^{36}-\text{S}-\text{NH}-\begin{array}{c} \text{O} \\ | \\ \text{C} \end{array}$

wherein R^{36} is alkyl as defined above.

As used herein the term "trifluoromethylthio" refers to a radical of the formula $\text{F}_3\text{C}-\text{S}-\begin{array}{c} \text{F} \\ | \\ \text{C} \end{array}$.

- 22 -

As used herein the term "trifluoromethylsulfonyl" refers to a radical of the formula $\text{F}_3\text{C}-\text{S}-\text{O}-\text{S}-\text{O}-\text{O}$.

As used herein the term "4-12 membered mono-nitrogen containing monocyclic or bicyclic ring" refers to a saturated or partially unsaturated monocyclic or bicyclic ring of 4-12 atoms and more preferably a ring of 4-9 atoms wherein one atom is nitrogen. Such rings may optionally contain additional heteroatoms selected from nitrogen, oxygen or sulfur. Included within this group are morpholine, piperidine, piperazine, thiomorpholine, pyrrolidine, proline, azacycloheptane and the like.

As used herein the term "benzyl" refers to the radical $\text{--CH}_2-\text{C}_6\text{H}_5$.

As used herein the term "phenethyl" refers to the radical $\text{--CH}_2\text{CH}_2-\text{C}_6\text{H}_5$.


As used herein the term "4-12 membered mono-nitrogen containing monosulfur or monoxygen containing heterocyclic ring" refers to a ring consisting of 4 to 12 atoms and more preferably 4 to 9 atoms wherein at least one atom is a nitrogen and at least one atom is oxygen or sulfur. Encompassed within this definition are rings such as thiazoline and the like.

As used herein the term "arylsulfonyl" or "arylsulfone" refers to a radical of the formula

$\text{R}^{37}-\text{S}(=\text{O})_2-$ wherein R^{37} is aryl as defined above.

- 23 -

As used herein the terms "alkylsulfoxide" or "arylsulfoxide" refer to radicals of the formula



wherein R^{38} is, respectively, alkyl or aryl as

defined above.

5 As used herein the term "phosphonic acid

derivative" refers to a radical of the formula $\begin{array}{c} \text{O} \\ \parallel \\ \text{P}-\text{OR}^{40} \\ | \\ \text{OR}^{39} \end{array}$

wherein R^{39} and R^{40} are the same or different H, alkyl, aryl or aralkyl.

10 As used herein the term "phosphinic acid derivatives" refers to a radical of the formula

$\begin{array}{c} \text{O} \\ \parallel \\ \text{P}-\text{OR}^{41} \\ | \\ \text{H} \end{array}$ wherein R^{41} is H, alkyl, aryl or aralkyl as

defined above.

As used herein the term "arylthio" refers to a radical of the formula $\begin{array}{c} \text{SR}^{42} \\ | \end{array}$ wherein R^{42} is aryl as

15 defined above.


As used herein the term "monocyclic heterocycle thio" refers to a radical of the formula $\begin{array}{c} \text{SR}^{43} \\ | \end{array}$

wherein R^{43} is a monocyclic heterocycle radical as defined above.

20 As used herein the terms "monocyclic heterocycle sulfoxide" and "monocyclic heterocycle sulfone" refer,

respectively, to radicals of the formula $\begin{array}{c} \text{O} \\ \parallel \\ \text{S}-\text{R}^{44} \end{array}$ and

- 24 -



as defined above.

As used herein the term "alkylcarbonyl" refers to a radical of the formula $\begin{array}{c} \text{O} \\ \parallel \\ \text{R}^{50}-\text{C}- \end{array}$ wherein R^{50} is alkyl as

5 defined above.

As used herein the term "arylcarbonyl" refers to a radical of the formula $\begin{array}{c} \text{O} \\ \parallel \\ \text{R}^{51}-\text{C}- \end{array}$ wherein R^{51} is aryl as

defined above.

As used herein the term "alkoxycarbonyl" refers to 10 a radical of the formula $\begin{array}{c} \text{O} \\ \parallel \\ \text{R}^{52}-\text{C}- \end{array}$ wherein R^{52} is alkoxy

as defined above.

As used herein the term "aryloxycarbonyl" refers to a radical of the formula $\begin{array}{c} \text{O} \\ \parallel \\ \text{R}^{51}-\text{O}-\text{C}- \end{array}$ wherein R^{51} is aryl

as defined above.

15 As used herein the term "haloalkylcarbonyl" refers to a radical of the formula $\begin{array}{c} \text{O} \\ \parallel \\ \text{R}^{53}-\text{C}- \end{array}$ wherein R^{53} is haloalkyl as defined above.

- 25 -

As used herein the term "haloalkoxycarbonyl"

refers to a radical of the formula $\text{R}^{53}-\text{O}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$ wherein R^{53}

is haloalkyl as defined above.

As used herein the term "alkylthiocarbonyl" refers

5 to a radical of the formula $\text{R}^{50}-\text{S}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$ wherein R^{50} is

alkyl as defined above.

As used herein the term "arylthiocarbonyl" refers

to a radical of the formula $\text{R}^{51}-\text{S}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$ wherein R^{51} is

aryl as defined above.

10 As used herein the term "acyloxymethoxycarbonyl" refers to a radical of the formula

$\text{R}^{54}-\text{O}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-\text{O}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$ wherein R^{54} is acyl as defined above.

As used herein the term "arylarnino" refers to a radical of the formula $\text{R}^{51}-\text{NH}-$ wherein R^{51} is aryl as defined above.

15 As used herein the term "polyalkylether" refers to commonly used glycols such as triethyleneglycol, tetraethylene glycol, polyethylene glycol and the like.

As used herein the term "alkylamido" refers to a

20 radical of the formula $\text{R}^{50}-\text{NH}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$ wherein R^{50} is alkyl as

defined above.

- 26 -

As used herein the term "N,N-dialkylamido" refers

to a radical of the formula $\text{R}^{50}-\text{N}(\text{C}_\text{R}^{50})-\text{C}(=\text{O})-$ wherein R^{50} is

the same or different alkyl group as defined above.

As used herein the term "pivaloyloxymethyl" refers

5 to a radical of the formula $\text{Me}-\text{C}(\text{Me})-\text{C}(=\text{O})-\text{O}-\text{CH}_2-$.

As used herein the term "acyloxy" refers to a radical of the formula $\text{R}^{\text{u}}-\text{O}-$ wherein R^{u} is acyl as defined above.

10 The term "composition" as used herein means a product which results from the mixing or combining of more than one element or ingredient.

15 The term "pharmaceutically acceptable carrier", as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a chemical agent.

20 The term "therapeutically effective amount" shall mean that amount of drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system or animal that is being sought by a researcher or clinician.

25 The following is a list of abbreviations and the corresponding meanings as used interchangeably herein:

$^1\text{H-NMR}$ = proton nuclear magnetic resonance
 AcOH = acetic acid
 $\text{BH}_3\text{-THF}$ = borane-tetrahydrofuran complex
 Bn = benzyl
30 BOC = tert-butoxycarbonyl
 ButLi = butyl lithium
 Cat. = catalytic amount
 CH_2Cl_2 = dichloromethane

- 27 -

	CH ₃ CN = acetonitrile
	CH ₃ I = iodomethane
	CHN analysis = carbon/hydrogen/nitrogen elemental analysis
5	CHNCl analysis = carbon/hydrogen/nitrogen/chlorine elemental analysis
	CHNS analysis = carbon/hydrogen/nitrogen/sulfur elemental analysis
	DCC = 1,3-dicyclohexylcarbodiimide
10	DIBAL = diisobutylaluminum hydride
	DIEA = diisopropylethylamine
	DMA = N,N-dimethylacetamide
	DMAP = 4-(N,N-dimethylamino)pyridine
	DMF = N,N-dimethylformamide
15	DSC = disuccinyl carbonate
	EDCl = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
	Et = ethyl
20	Et ₂ O = diethyl ether
	Et ₃ N = triethylamine
	EtOAc = ethyl acetate
	EtOH = ethanol
	FAB MS = fast atom bombardment mass spectroscopy
25	g = gram(s)
	GIHA = meta-guanidinohippuric acid
	GIHA HCl = meta-guanidinohippuric acid hydrochloride
	HPLC = high performance liquid chromatography
30	IBCF = isobutylchloroformate
	i-Pr = iso propyl
	i-Prop = iso propyl
	K ₂ CO ₃ = potassium carbonate
	KOH = potassium hydroxide
	KSCN = potassium thiocyanate
35	LiOH = lithium hydroxide
	MCPBA = m-chloroperoxybenzoic acid or m-chloroperbenzoic acid
	Me = methyl
	MeOH = methanol
40	MesCl = methanesulfonylchloride
	mg = milligram
	MgSO ₄ = magnesium sulfate
	ml = milliliter
	mL = milliliter
45	MS = mass spectroscopy
	N ₂ = nitrogen
	NaCNBH ₃ = sodium cyanoborohydride
	NaH = sodium hydride
	NaHCO ₃ = sodium bicarbonate
50	NaOH = sodium hydroxide
	Na ₂ PO ₄ = sodium phosphate
	Na ₂ SO ₄ = sodium sulfate
	NET ₃ = triethylamine
	NH ₄ HCO ₃ = ammonium bicarbonate
55	NH ₄ ⁺ HCO ₃ = ammonium formate

- 28 -

NMM = N-methylmorpholine
NMR = nuclear magnetic resonance
RPHPLC = reverse phase high performance liquid chromatography

5 RT = room temperature

Pd/C = palladium on carbon

Ph = phenyl

Pt/C = platinum on carbon

t-BOC = tert-butoxycarbonyl

10 TFA = trifluoroacetic acid

THF = tetrahydrofuran

TMEDA = trimethylethylenediamine

TMS = trimethylsilyl

Δ = heating the reaction mixture

15

The compounds as shown in Formulas I-V can exist in various isomeric forms and all such isomeric forms are meant to be included. Tautomeric forms are also included as well as pharmaceutically acceptable salts of such isomers and tautomers.

In the structures and formulas herein, a bond drawn across a bond of a ring can be to any available atom on the ring.

The term "pharmaceutically acceptable salt" refers 25 to a salt prepared by contacting a compound of Formula I with an acid whose anion is generally considered suitable for human consumption. Examples of pharmacologically acceptable salts include the hydrochloride, hydrobromide, hydroiodide, sulfate, 30 phosphate, acetate, propionate, lactate, maleate, malate, succinate, tartrate salts and the like. All of the pharmacologically acceptable salts may be prepared by conventional means. (See Berge et al., J Pharm. Sci. 66(1), 1-19 (1977) for additional examples of 35 pharmaceutically acceptable salts.)

For the selective inhibition or antagonism of α,β , integrins, compounds of the present invention may be administered orally, parenterally, or by inhalation spray, or topically in unit dosage formulations 40 containing conventional pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes, for example, subcutaneous,

- 29 -

intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.

The compounds of the present invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.

5 Therapeutically effective doses of the compounds required to prevent or arrest the progress of or to treat the medical condition are readily ascertained by

10 one of ordinary skill in the art using preclinical and clinical approaches familiar to the medicinal arts.

Accordingly, the present invention provides a method of treating conditions mediated by selectively inhibiting or antagonizing the α,β , cell surface receptor which method comprises administering a therapeutically effective amount of a compound selected from the class of compounds depicted in Formulas I-V, wherein one or more compounds of the Formulas I-V is administered in association with one or more non-toxic, pharmaceutical acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and if desired other active ingredients. More specifically, the present invention provides a method for inhibition of the α,β , cell surface receptor. Most preferably the present invention provides a method for inhibiting bone resorption, treating osteoporosis, inhibiting humoral hypercalcemia of malignancy, treating Paget's disease, inhibiting tumor metastasis, inhibiting neoplasia

25 (solid tumor growth), inhibiting angiogenesis including tumor angiogenesis, treating diabetic retinopathy, inhibiting arthritis, psoriasis and periodontal disease, and inhibiting smooth muscle cell migration including restenosis.

30 35 Based upon standard laboratory experimental techniques and procedures well known and appreciated by those skilled in the art, as well as comparisons with

- 30 -

compounds of known usefulness, the compounds of Formula I can be used in the treatment of patients suffering from the above pathological conditions. One skilled in the art will recognize that selection of the most 5 appropriate compound of the invention is within the ability of one with ordinary skill in the art and will depend on a variety of factors including assessment of results obtained in standard assay and animal models.

Treatment of a patient afflicted with one of the 10 pathological conditions comprises administering to such a patient an amount of compound of the Formula I which is therapeutically effective in controlling the condition or in prolonging the survivability of the patient beyond that expected in the absence of such 15 treatment. As used herein, the term "inhibition" of the condition refers to slowing, interrupting, arresting or stopping the condition and does not necessarily indicate a total elimination of the condition. It is believed that prolonging the 20 survivability of a patient, beyond being a significant advantageous effect in and of itself, also indicates that the condition is beneficially controlled to some extent.

As stated previously, the compounds of the 25 invention can be used in a variety of biological, prophylactic or therapeutic areas. It is contemplated that these compounds are useful in prevention or treatment of any disease state or condition wherein the α,β , integrin plays a role.

30 The dosage regimen for the compounds and/or compositions containing the compounds is based on a variety of factors, including the type, age, weight, sex and medical condition of the patient; the severity of the condition; the route of administration; and the 35 activity of the particular compound employed. Thus the dosage regimen may vary widely. Dosage levels of the order from about 0.01 mg to about 100 mg per kilogram

- 31 -

of body weight per day are useful in the treatment of the above-indicated conditions.

The active ingredient administered by injection is formulated as a composition wherein, for example, 5 saline, dextrose or water may be used as a suitable carrier. A suitable daily dose would typically be about 0.01 to 10 mg/kg body weight injected per day in multiple doses depending on the factors listed above.

For administration to a mammal in need of such 10 treatment, the compounds in a therapeutically effective amount are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of 15 alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, gelatin, acacia, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and tableted or encapsulated 20 for convenient administration. Alternatively, the compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and 25 modes of administration are well and widely known in the pharmaceutical art.

The pharmaceutical compositions useful in the present invention may be subjected to conventional pharmaceutical operations such as sterilization and/or 30 may contain conventional pharmaceutical adjuvants such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, etc.

The general synthetic sequences for preparing the compounds useful in the present invention are outlined 35 in Schemes I-XXI. Both an explanation of, and the actual procedures for, the various aspects of the present invention are described where appropriate. The

- 32 -

following Schemes and Examples are intended to be merely illustrative of the present invention, and not limiting thereof in either scope or spirit. Those with skill in the art will readily understand that known 5 variations of the conditions and processes described in the Schemes and Examples can be used to synthesize the compounds of the present invention.


Unless otherwise indicated all starting materials and equipment employed were commercially available.

10

- 111 -

Example 1

Preparation of (±)ethyl β -[[2-[[3-[(aminoiminomethyl)-
amino]phenyl]carbonyl]amino]acetyl]amino]pyridine-3-
5 propanoate, bis(trifluoroacetate) salt



Step A

15 To 3-pyridine carboxaldehyde (300 ml) in 2-
propanol (3 liters) was added ammonium acetate (297 g)
followed by malonic acid (398 g). The reaction mixture
was stirred at reflux for 5 hours. The precipitate was
filtered while hot and washed with hot isopropanol (2
20 liters). The resulting white solid was then dried to
yield DL-3-amino-3-(3-pyridyl)propionic acid (220 g) as
a white solid.

NMR and MS were consistent with the desired
product.

25

Step B

DL-3-amino-3-(3-pyridyl)propionic acid (220 g)
from Step A was slurried in absolute ETOH (3.6 liters).
HCl gas (one lecture bottle - $\frac{1}{2}$ lb) was bubbled into
30 the reaction while stirring over 40 minutes (slow
exotherm to 61°C). The slurry was then heated at
reflux for 4 hours (a solution forms after 1 to 1.5
hours). The reaction mixture was cooled to 5°C in an
ice bath. After stirring at 5°C for 1.5 hours, the
35 resulting white precipitate was filtered and washed
thoroughly with ether. After drying under vacuum at
50°C, the yield of ethyl DL-3-amino-3-(3-

- 112 -

pyridyl)propionate dihydrochloride was 331.3 g as a white solid.

NMR and MS were consistent with the desired product.

5

Step C

To ethyl DL-3-amino-3-(3-pyridyl)propionate dihydrochloride (220.6 g, 0.83 mole) from Step B in anhydrous THF (2 liters) and triethylamine (167.2 g, 1.65 moles), N-t-BOC-glycine N-hydroxysuccinimide ester (225 g, 0.826 moles) (Sigma) was added in several portions at 5-10°C (no exotherm). The reaction mixture was stirred overnight at room temperature. The resulting precipitate was filtered and washed with THF. The solvent from the filtrate was then removed under vacuum. The residue was taken up in ethyl acetate (2.3 liters). The ethyl acetate layer was washed with saturated sodium bicarbonate (2 x 900 ml) and H₂O (3 x 900 ml), dried over MgSO₄, and removed under vacuum. The residue was slurried overnight in 10% ethyl acetate/hexane (2.5 liters). The precipitate was filtered, washed with 10% ethyl acetate/hexane (1 liter), then hexane, then dried to yield ethyl β -[[2-[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]-pyridine-3-propanoate (233 g) as a white solid.

NMR and MS were consistent with the desired structure.

Step D

Ethyl β -[[2-[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]-pyridine-3-propanoate (from Step C) (232 g, 0.66 mole) was dissolved in warm dioxane (1 liter). After cooling to room temperature, 4M HCl in dioxane (1.6 liters) (Aldrich) was slowly added. A white precipitate formed after several minutes and then turned to a thick goo. After 2 hours, the solvent was decanted off. The goo was slurried in ether and the

- 113 -

ether decanted off until a white solid resulted. This was dried under vacuum to yield ethyl β -[(2-aminoacetyl)amino]pyridine-3-propanoate, bis hydrochloride salt (224.2 g) as a white hygroscopic

5 solid.

NMR and MS were consistent with the desired structure.

Step E

10 To 3,5-dimethylpyrazole-1-carboxamidine nitrate (6 g, 0.03 mole) (Aldrich) and diisopropylamine (3.8 g, 0.03 mole) in dioxane (20 ml) and H₂O (10 ml) was added 3-aminobenzoic acid (2.7 g, 0.02 mole). The reaction was stirred at reflux for 2.5 hours then overnight at 15 room temperature. The resulting precipitate was filtered, washed with dioxane/H₂O and dried. The precipitate was then slurried in H₂O and acidified with concentrated HCl until a solution formed. The solvent was removed under vacuum and the residue was slurried 20 twice in ether (ether decanted off). The product was dried under vacuum to yield 3-guanidinobenzoic acid hydrochloride (1.77 g) as a white solid. MS and NMR were consistent with the desired structure.

25 Step F

To the product from Step E (0.49 g, 0.0023 mole) and N-methylmorpholine (0.23 g, 0.0023 mole) in anhydrous DMF (8 ml) was added isobutylchloroformate (0.31 g, 0.0023 mole) at ice bath temperature. After 30 stirring for 5 minutes at ice bath temperature, a slurry of the product from Step D (0.73 g, 0.0023 mole) and N-methylmorpholine (0.46 g, 0.0045 mole) in anhydrous DMF (8 ml) was added in one portion. The reaction mixture was stirred overnight at room 35 temperature. The solvent was removed under vacuum on a 78°C water bath and the product was isolated by RP-HPLC to yield (\pm)ethyl β -[[2-[[3-[(aminoiminomethyl)-


- 114 -

amino]phenyl]carbonyl]amino]acetyl]amino]pyridine-3-propanoate, bis(trifluoroacetate) salt (800 mg) as a hygroscopic white solid. MS and NMR were consistent with the desired structure.

- 115 -

Example 2

Preparation of $(\pm)\beta$ -[[2-[[3-[(aminoiminomethyl)amino]-phenyl]carbonyl]amino]acetyl]amino]pyridine-3-propanoic acid, bis(trifluoroacetate) salt




To the product from Example 1 (700 mg, 0.001 mole), in H₂O (20 ml) was added LiOH (160 mg, 0.0038 mole). The reaction mixture was stirred for 1 hour at room temperature. After lowering the pH to ≈5 with TFA, the product was isolated by RPHPLC to yield $(\pm)\beta$ -[[2-[[3-[(aminoiminomethyl)amino]-phenyl]carbonyl]amino]acetyl]amino]pyridine-3-propanoic acid, bis(trifluoroacetate) salt (640 mg) as a white solid. MS and NMR were consistent with the desired structure.

- 116 -

Example 3

Preparation of (±)ethyl β -[[2-[[3-[(aminoiminomethyl)-amino]phenyl]carbonyl]amino]acetyl]amino]-benzenepropanoate, trifluoroacetate salt




15 The above compound was prepared according to the methodology of Example 1, substituting an equivalent amount of benzaldehyde for 3-pyridinecarboxaldehyde in Step A.

NMR and MS were consistent with the desired structure.

- 117 -

Example 4

Preparation of (±) β -[[2-[[3-[(aminoiminomethyl)-
5 amino]phenyl]carbonyl]amino]acetyl]amino]benzene-
propanoic acid, trifluoroacetate salt




15 To the product of Example 3 (0.37 g, 0.0007 mole) in H₂O (10 ml) was added LiOH (80 mg, 0.002 mole). The reaction mixture was stirred at room temperature for 1 hour. The pH was lowered to ≈ 3 with TFA and the product was isolated by RP-HPLC to yield β -[[2-[[3-
20 [(aminoiminomethyl)amino]phenyl]carbonyl]-
amino]acetyl]amino]benzene propanoic acid,
trifluoroacetate salt (280 mg) as a white solid. MS
and NMR were consistent with the desired structure.

- 118 -

Example 5

Preparation of (±)ethyl β -[[2-[[3-[(aminoiminomethyl)-
5 amino]phenyl]carbonyl]amino]acetyl]amino]-1,3-
benzodioxole-5-propanoate, trifluoroacetate salt



15 The above compound was prepared according to the methodology of Example 1, substituting the equivalent amount of piperonal (Aldrich) for 3-pyridinecarbox-aldehyde in Step A.


20 MS and NMR were consistent with the desired structure.

- 119 -

Example 6

Preparation of $(\pm)\beta$ -[[2-[[3-[(aminoiminomethyl)amino]-phenyl]carbonyl]amino]acetyl]amino]-1,3-benzodioxole-5-propanoic acid, trifluoroacetate salt

10




To the product of Example 5 (0.35 g, 0.0006 mole)
15 in H₂O (40 ml) and CH₃CN (5 ml) was added LiOH (70 mg, 0.0017 mole). The reaction mixture was stirred at room temperature for 1 hour. The pH was lowered to \approx 4.5 with TFA and the product was isolated by RPHPLC to yield $(\pm)\beta$ -[[2-[[3-[(aminoiminomethyl)-
20 amino]phenyl]carbonyl]amino]acetyl]amino]-1,3-benzodioxole-5-propanoic acid, trifluoroacetate salt (280 mg) as a white solid. MS and NMR were consistent with the desired structure.

- 120 -

Example 7

Preparation of (±)ethyl β -[[2-[[3-[(aminoiminomethyl)-
5 amino]naphthalen-1-yl]carbonyl]amino]acetyl]amino]-
pyridine-3-propanoate, bis(trifluoroacetate) salt



(RACEMIC)

15

Step A

To methyl 3-nitro-1-naphthoate (2.5 g, 0.011
mole) (Aldrich) in MeOH/H₂O (40 ml) (1:1) was added LiOH
(1.8 g, 4 equivalents). The solution was stirred
20 overnight at room température. The solvent was removed
under a stream of N₂. The residue was dissolved in H₂O
and the solution acidified with concentrated HCl. The
resulting precipitate was filtered, washed with H₂O and
dried to yield 3-nitro-1-naphthoic acid (2.18 g) as a
25 white solid.

Step B

3-Nitro-1-naphthoic acid (1.77 g, 0.008 mole) was
dissolved in a minimum of warm MeOH. 10% Pd/C (300 mg)
30 was added and the reaction shaken on a Parr shaker
under 50 psi H₂ for 5 hours. The catalyst was filtered
through celite and the solvent was removed under
vacuum. The residue was dried to yield 3-amino-1-
naphthoic acid (1.43 g) as a pink colored solid.

35

- 121 -

Step C

To 3,5-dimethylpyrazole-1-carboxamidine nitrate (1.6 g, 0.008 mole) (Aldrich) and diisopropylethylamine (1.02 g, 0.008 mole) in dioxane (5 ml) and H₂O (2.5 ml) 5 was added 3-amino-1-naphthoic acid (1 g, 0.0053 mole). The reaction mixture was stirred at reflux overnight. The reaction was cooled to room temperature and the precipitate was filtered, washed with dioxane/H₂O then dried. The precipitate was then slurried in H₂O and 10 acidified with concentrated HCl. The solvent was removed under vacuum on a 70°C water bath. The residue was slurried in ether 3 x (ether decanted off), then dried under vacuum to yield 3-guanidino-1-naphthoic acid hydrochloride (460 mg) as a white solid.

15

Step D


To 3-guanidino-1-naphthoic acid hydrochloride (400 mg, 0.0015 mole) and N-methylmorpholine (150 mg) in anhydrous DMF (8 ml) was added isobutylchloroformate 20 (210 mg) at ice bath temperature. After stirring at ice bath temperature for 5 minutes, a slurry of the product from Example 1, Step D (490 mg, 0.0015 mole), N-methylmorpholine (300 mg) and anhydrous DMF (6 ml) was added in one portion. The reaction mixture was 25 stirred overnight at room temperature. The solvent was removed under vacuum on a 78°C water bath. The product was isolated by RP-HPLC to yield (±)ethyl β -[[2-[[[1-[(aminoiminomethyl)amino]naphthalen-3-yl]carbonyl]-amino]acetyl]amino]pyridine-3-propanoate, 30 bis(trifluoroacetate)salt (410 mg) as a white solid.

NMR and MS were consistent with the desired structure.

- 122 -

Example 8

Preparation of $(\pm)\beta-[[2-[[[3-[(aminoiminomethyl)-amino]naphthalen-1-yl]carbonyl]amino]acetyl]amino]-5\text{pyridine-3-propanoic acid, bis(trifluoroacetate) salt}$




(RACEMIC)

15 To the product of Example 7, Step D (280 mg, 0.0004 mole) in H₂O (15 ml) and CH₃CN (2 ml) was added (70 mg, 0.0016 mole) LiOH. The reaction mixture was stirred at room temperature for 1 hour. The pH was lowered to 5 with TFA and the product was isolated by 20 RPHPLC to yield $(\pm)\beta-[[2-[[[1-[(aminoiminomethyl)-amino]naphthalen-3-yl]carbonyl]amino]acetyl]amino]pyridine-3-propanoic acid, bis(trifluoroacetate) salt$ (240 mg) as a hygroscopic white solid. MS and NMR were consistent with the desired structure.

- 123 -

Example 9

Preparation of (\pm)ethyl β -[[2-[[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]carbonyl]amino]acetyl]-5-amino]pyridine-3-propanoate, bis(trifluoroacetate) salt

Step A

15 To 2-methylthio-2-imidazoline hydroiodide (14.6 g, 0.06 mole) (Aldrich) and diisopropylethylamine (7.6 g, 0.06 mole) in dioxane (40 ml) and H₂O (20 ml) was added 3-aminobenzoic acid (5.4 g, 0.04 mole). The reaction was stirred overnight at reflux. The solution was cooled in an ice bath and the resulting precipitate was 20 filtered and washed with dioxane. The crude product was purified by RPHPLC to yield 3-(2-aminoimidazoline)-benzoic acid (800 mg).

Step B

25 To the product from Step A (400 mg, 0.00125 mole) and N-methylmorpholine (130 mg, 0.00125 mole) in anhydrous DMF (8 ml) was added isobutylchloroformate (170 mg, 0.00125 mole). After stirring at ice bath temperature for 5 minutes, the product from Example 1, 30 Step D (410 mg, 0.00125 mole) and N-methylmorpholine (250 mg, 0.0025 mole) in anhydrous DMF (6 ml) was added in one portion. The reaction mixture was stirred overnight at room temperature. The solvent was removed under vacuum on a 79°C water bath and the product was 35 isolated by RPHPLC to yield (\pm)ethyl β -[[2-[[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]carbonyl]amino]-acetyl]amino]pyridine-3-propanoate,

- 124 -


bis(trifluoroacetate) salt (600 mg) as a hygroscopic white solid. MS and NMR were consistent with the desired structure.

- 125 -

Example 10

Preparation of $(\pm)\beta-[[2-[[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]carbonyl]amino]acetyl]amino]pyridine-3$ -propanoic acid, bis(trifluoroacetate) salt

10




To the product of Example 9, Step B (450 mg, 0.00068 mole) in H₂O (20 ml) was added LiOH (110 mg, 0.0027 mole). The reaction mixture was stirred at room temperature for 1 hour. The pH was lowered to 5 with TFA and the product was isolated by RPHPLC to yield $(\pm)\beta-[[2-[[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]carbonyl]amino]acetyl]amino]pyridine-3$ -propanoic acid, bis(trifluoroacetate) salt (250 mg) as a hygroscopic white solid. MS and NMR were consistent with the desired structure.

- 126 -

Example 11

Preparation of (±) ethyl β -[[2-[[3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonyl]-amino]acetyl]amino]pyridine-3-propanoate, bis(trifluoroacetate) salt

15 Step A

To 1-aza-2-methoxy-1-cycloheptene (3.67 g, 0.0288 mole) (Aldrich) in absolute ethanol (20 ml) was added 3-aminobenzoic acid hydrochloride (5 g, 0.0288 mole). A solution quickly formed. The reaction mixture was 20 stirred overnight at room temperature. The resulting precipitate was filtered, washed with ether and dried under vacuum to yield 3-(1-aza-2-amino-1-cycloheptene)-benzoic acid (4.9 g).

25 Step B

To the product from Step A (0.5 g, 0.0019 mole) and N-methylmorpholine (0.19 g, 0.0019 mole) in anhydrous DMF (8 ml) was added isobutylchloroformate (0.25 g, 0.0019 mole) at ice bath temperature. After 30 stirring at ice bath temperature for 5 minutes, a slurry of the product from Example 1, Step D (0.6 g, 0.0019 mole) and N-methylmorpholine (0.38 g, 0.0037 mole) in anhydrous DMF (7 ml) was added in one portion. The reaction mixture was stirred overnight at room 35 temperature. The solvent was removed under vacuum on a 78°C water bath and the product was isolated by RPHPLC.

- 127 -


to yield the title compound (490 mg). NMR and MS were consistent with the desired structure.

- 128 -

Example 12

Preparation of (\pm) β -[[2-[[3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonyl]amino]acetyl]amino]-5-pyridine-3-propanoic acid, bis(trifluoroacetate) salt

10




To the product of Example 11, Step B (400 mg, 0.00058 mole) in H₂O (20 ml) was added LiOH (80 mg, 0.0019 mole). The reaction mixture was stirred at room temperature for 1 hour. The pH was lowered to 4.5 with TFA and the product was isolated by RP-HPLC to yield 320 mg of (\pm) β -[[2-[[3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonyl]amino]acetyl]amino]pyridine-3-propanoic acid, bis(trifluoroacetate) salt as a white solid. MS and NMR are consistent with the desired structure.

- 129 -

Example 13

Preparation of (±)ethyl β -{[2-[[3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonyl]amino]-acetyl]amino)-1,3-benzodioxole-5-propanoate, TFA salt

10




15 The above compound was prepared according to the methodology of Example 11, substituting the equivalent amount of piperonal (Aldrich) for 3-pyridine-carboxaldehyde in Example 1, Step A, in Example 11, Step B.

20 MS and NMR were consistent with the desired structure.

- 130 -

Example 14

Preparation of (\pm) β -[[2-[[3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonyl]amino]acetyl]amino]-1,3-benzodioxole-5-propanoic acid, TFA salt




15 To the product of Example 13 (0.46 g, 0.00091 mole) in H_2O (10 ml) and dioxane (7.5 ml) was added LiOH (80 mg, 0.0018 mole). The reaction was stirred at room temperature for 2 hours. The pH was lowered to 5 with 20 TFA and the product was isolated by RPHPLC to yield (\pm) β -[[2-[[3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonyl]amino]acetyl]amino]-1,3-benzodioxole-5-propanoic acid (440 mg) as a white solid. MS and NMR were consistent with the desired 25 structure.

- 131 -

Example 15

Preparation of $(\pm)\beta$ -[[2-[[3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonyl]amino]acetyl]amino]-5-benzenepropanoic acid, trifluoroacetate salt

10




The above compound was prepared according to the methodology of Example 12, substituting the equivalent amount of benzaldehyde for 3-pyridinecarboxaldehyde in Example 1, Step A, and further used in Example 1, Step D as described in Example 11, Step B.

MS and NMR were consistent with the desired structure.

- 132 -

Example 16

Preparation of (±) ethyl β -[[2-[[3-[(3,4-dihydro-2H-pyrrol-5-yl)amino]phenyl]carbonyl]amino]acetyl]amino]-5-pyridine-3-propanoate, bis(trifluoroacetate) salt



15 The above compound was prepared according to the methodology of Example 11, substituting 1-aza-2-methoxy-1-cyclopentene* for 1-aza-2-methoxy-1-cycloheptene in Step A. MS and NMR were consistent with the desired structure.


* 1-aza-2-methoxy-1-cyclopentene was made as follows: To 2-pyrrolidinone (2.7 g, 0.033 mole) in CH_2Cl_2 (100 ml) was added trimethyloxonium 25 tetrafluoroborate (10 g) (Aldrich). The reaction was stirred at room temperature for 2 days. Saturated NaHCO_3 was added and after shaking in a separatory funnel, the CH_2Cl_2 was separated and distilled off. 1 g of desired product was 30 isolated by further distillation at atmospheric pressure collecting the portion boiling at $\approx 120^\circ\text{C}$.

- 133 -

Example 17

Preparation of β -[[2-[[3-[(3,4-dihydro-2H-pyrrol-5-yl)amino]phenyl]carbonyl]amino]acetyl]amino]pyridine-3-propanoic acid, bis(trifluoroacetate) salt

10




15

To the product of Example 16 (380 mg, 0.00057 mole) in H₂O (15 ml) was added LiOH (100 mg, 0.002 mole). The reaction was stirred at room temperature for 2 hours. The pH was lowered to 5 with TFA and the 20 product was isolated by RPHPLC to yield β -[[2-[[3-[(3,4-dihydro-2H-pyrrol-5-yl)amino]phenyl]carbonyl]amino]acetyl]amino]pyridine-3-propanoic acid, bis(trifluoroacetate) salt (150 mg) as a white solid. MS and NMR were consistent with the desired structure.

- 134 -

Example 18

Preparation of (\pm) ethyl β -{[1-[[3-
[(aminoiminomethyl)amino]phenyl]carbonyl]amino]-1-
5 cyclopropyl]carbonyl]amino]pyridine-3-propanoate,
bis(trifluoroacetate) salt




The above compound was prepared according to the methodology of Example 1, substituting an equivalent amount of 1-(N-t-Boc-amino)cyclopropane-N-
20 hydroxysuccinimide carboxylate (Sigma) for N-t-BOC-glycine N-hydroxysuccinimide ester in Example 1, Step C.

MS and NMR were consistent with the desired structure.

- 135 -

Example 19

Preparation of β -[[1-[[3-[(aminoiminomethyl)amino]-phenyl]carbonyl]amino]cycloprop-1-yl]carbonyl]amino]-pyridine-3-propanoic acid, bis(trifluoroacetate) salt




To the product of Example 18 (220 mg, 0.00033 mole) in H_2O (15 ml) was added LiOH (60 mg, 0.0013 mole). The reaction was stirred at room temperature for 1.5 hours. The pH was lowered to 3 with TFA and 20 the product was isolated by RP-HPLC to yield β -[[1-[[3-[(aminoiminomethyl)amino]phenyl]carbonyl]amino]-cycloprop-1-yl]carbonyl]amino]pyridine-3-propanoic acid, bis(trifluoroacetate) salt (170 mg) as a white acid. MS and NMR were consistent with the desired 25 structure.

- 136 -

Example 20

Preparation of (±)ethyl β -[[2-[[[4-chloro-3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonyl]amino]-5-acetyl]amino]pyridine-3-propanoate, bis TFA salt

10



(RACEMIC)

15


The above compound was prepared according to the methodology of Example 11, substituting an equivalent amount of 3-amino-4-chloro-benzoic acid hydrochloride (Aldrich) for 3-amino-benzoic acid hydrochloride in Example 11, Step A. MS and NMR were consistent with the desired structure.

- 137 -

Example 21

Preparation of (\pm) β -[[2-[[[4-chloro-3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonyl]amino]-acetyl]amino]pyridine-3-propanoic acid, bis TFA Salt

10



(RACEMIC)


15

To the product of Example 20 (150 mg, 0.0002 mole) in H₂O (15 ml) was added LiOH (40 mg, 0.0008 mole). The reaction was stirred at room temperature for 1 hour. The pH was lowered to 3 with TFA and the product was isolated by RP-HPLC to yield (\pm) β -[[2-[[[4-chloro-3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonyl]amino]acetyl]amino]pyridine-3-propanoic acid (100 mg) as a white solid. MS and NMR were consistent with the desired structure.

- 138 -

Example 22

Preparation of (\pm) β -[[2-[[[3,5-bis[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonyl]amino]-acetyl]amino]pyridine-3-propanoic acid, tris(trifluoroacetate) salt




(RACEMIC)

The above compound was prepared according to the methodology of Example 12, substituting an equivalent amount of 3,5-diaminobenzoic acid dihydrochloride (0.3 equivalents) (Fluka) for 3-aminobenzoic acid hydrochloride in Example 11, Step A. MS and NMR were consistent with the desired structure.

- 139 -

Example 23

Preparation of (\pm) ethyl β -[[2-[[3-[[imino-
[(phenylmethyl)amino]methyl]amino]phenyl]carbonyl]-
5 amino]acetyl]amino]pyridine-3-propanoate,
bis(trifluoroacetate) salt

Step A

1-(3-Carboxyphenyl)-2-thiourea (5 g, 0.025 mole) (Trans World Chemicals) in THF (75 ml) and CH_3I (3.62 g, 0.025 mole) were stirred at reflux for 2 hours. The solvent was removed under vacuum and the residue was slurried in ether (3X), (the ether decanted off each time) to yield, after drying under vacuum, N-(3-carboxyphenyl)-S-methylisothiouronium hydroiodide (7.8 g) as a yellow solid.

Step B

To the product of Step A (1.5 g, 0.0044 mole) and diisopropylethylamine (0.57 g, 0.0044 mole) in H_2O (5 ml) and dioxane (5 ml) was added benzylamine (0.48 g, 0.0044 mole). The reaction mixture was heated at reflux for 6 hours. The reaction was cooled to room temperature and a precipitate formed. Dioxane (6 ml) was added and the slurry was stirred overnight at room temperature. The precipitate was filtered, washed with dioxane/ H_2O , dried, slurried in H_2O , and acidified with concentrated HCl. The solvent was removed under vacuum

- 140 -

and the residue was slurried in ether (3X; ether decanted off each time). After drying, 1-(3-carboxyphenyl)-2-benzylguanidine hydrochloride (800 mg) was isolated as a white solid. MS and NMR were
5 consistent with the desired structure.


Step C

The title compound was prepared according to Example 1, Step F, substituting an equivalent amount of
10 the product from Step B above for the product from Example 1, Step E in Step F. MS and NMR were consistent with the desired structure.

- 141 -

Example 24

Preparation of (\pm) β -[[2-[[3-[[imino[(phenylmethyl)-
amino]methyl]amino]phenyl]carbonyl]amino]acetyl]amino]-
5 pyridine-3-propanoic acid, bis(trifluoroacetate) salt




To the product of Example 23, Step C (330 mg, 0.00045 mole) in H₂O (20 ml) was added LiOH (80 mg). The reaction was stirred at room temperature for 1 hour. The pH was lowered to 3 with TFA and the product was isolated by RP-HPLC to yield (\pm) β -[[2-[[3-
5 [imino[(phenylmethyl)amino]methyl]amino]phenyl]-
[carbonyl]amino]acetyl]amino]pyridine-3-propanoic acid,
bis(trifluoroacetate) salt (330 mg) as a white solid.
25 MS and NMR were consistent with the desired structure.

- 142 -

Example 25

Preparation of (\pm) ethyl β -[[2-[[3-
[(iminophenylmethyl)amino]phenyl]carbonyl]amino]acetyl]
5 amino]pyridine-3-propanoate, bis(trifluoroacetate) salt

10

15 Step A

To ethyl benzimidate hydrochloride (3 g, 0.016 mole) (Fluka) and (2.1 g, 0.016 mole) diisopropylethylamine in H₂O (15 ml) and dioxane (15 ml) was added 3-aminobenzoic acid (2.22 g, 0.016 mole) (Aldrich). The reaction mixture was stirred at room temperature for 4 days. The resulting precipitate was filtered, washed with dioxane/H₂O and dried. The precipitate was slurried in H₂O and acidified with concentrated HCl. The solvent was removed under vacuum and the residue was slurried in ether. The ether was decanted off and the residue dried under vacuum to yield N-(3-carboxyphenyl)benzimidine hydrochloride (700 mg) as a white solid. MS and NMR were consistent with the desired structure.

30


Step B

The title compound was prepared according to the methodology of Example 1, Step F, substituting an equivalent amount of the product from Step A above for the product from Example 1, Step E in Step F. MS and NMR were consistent with the desired structure.

- 143 -

Example 26

Preparation of (\pm) β -[[2-[[3-[(iminophenylmethyl)-
5 amino]phenyl]carbonyl]amino]acetyl]amino]pyridine-3-
propanoic acid, bis(trifluoroacetate) salt



15


To the product of Example 25, Step B (240 mg, 0.0034 mole) in H₂O (20 ml) was added LiOH (50 mg). The reaction mixture was stirred at room temperature for 35 minutes. The pH was lowered to 3 with TFA and the product was isolated by RPHPLC to yield (\pm) β -[[2-[[[3-[(imino phenylmethyl]amino]phenyl]carbonyl]amino]acetyl]amino]pyridine-3-propanoic acid, bis(trifluoroacetate) salt (120 mg) as a white solid. MS and NMR were consistent with the desired structure.

- 144 -

Example 27

Preparation of β -[[2-[[[3-[(aminoiminomethyl)amino]-phenyl]carbonyl]amino]acetyl]amino]-3,5-dichlorobenzene propanoic acid, trifluoroacetate salt

10




15

The above compound was prepared according to the method of Example 2 substituting an equivalent amount of 3,5-dichlorobenzaldehyde (Aldrich) for 3-pyridinecarboxaldehyde in Example 1, Step A.

- 145 -

Example 30

Preparation of β S-[[2-[[[3-[(3,4,5,6-tetrahydro-2H-
azepin-7-yl)amino]phenyl]carbonyl]amino]acetyl]amino]-
5 4-pentynoic acid, trifluoroacetate salt




15 The above compound was prepared according to the
method of Example 12, substituting an equivalent amount
of ethyl 3-S-amino-4-pentynoate hydrochloride (J. Med.
Chem. 1995, 38, 3378-2394) for ethyl DL-3-amino-3-(3-
pyridyl)propionate dihydrochloride in Example 1, Step C
20 and further used in Example 1, Step D as described in
Example 11, Step B.

- 146 -

Example 34

Preparation of β S-[[2-[[3-[[imino(1-pyrrolidinyl)-
5 methyl]amino]phenyl]carbonyl]amino]acetyl]amino]-4-
pentynoic acid, trifluoroacetate salt




20 The above compound was prepared according to
methodology of Example 24, substituting an equivalent
amount of pyrrolidine for benzylamine in Example 23,
Step B and an equivalent amount of ethyl 3-S-amino-4-
25 pentynoate hydrochloride for ethyl DL-3-amino-3-(3-
pyridyl)propionate dihydrochloride in Example 1, Step C
and further used in Example 1, Step D as described in
Example 23, Step C.

- 147 -

Example 35

Preparation of β -S-[[2-[[3-[(aminoiminomethyl)amino]-2,5,6-trifluorophenyl]carbonyl]amino]acetyl]amino]-4-pentyanoic acid, trifluoroacetate salt

10




15

The above compound was prepared according to the methodology of Example 2, substituting an equivalent amount of ethyl 3-S-amino-4-pentyanoate hydrochloride for ethyl DL-3-amino-3-(3-pyridyl)propionate dihydrochloride in Example 1, Step C and substituting an equivalent amount of 3-amino-2,5,6-trifluorobenzoic acid for 3-aminobenzoic acid in Example 1, Step E.

- 148 -

Example 36

Preparation of (\pm) β -[[2-[[3-[(aminoiminomethyl)-
amino]phenyl]carbonyl]amino]acetyl]amino]-3,5-
5 bis(trifluoromethyl)benzenepropanoic acid,
trifluoroacetate salt

15 Step A

Preparation of ethyl (\pm) β -[[2-[[3-
[(aminoiminomethyl)amino]phenyl]carbonyl]amino]acetyl]-
amino]-3,5-bis(trifluoromethyl)benzenepropanoate.

20 The above compound was prepared according to the
methodology of Example 1, substituting the equivalent
amount of 3,5-bis-trifluoromethylbenzaldehyde (Aldrich)
for 3-pyridinecarboxaldehyde in Step A.

NMR and mass spectrometry were consistent with the
desired structure.

25

Step B


To 260 mg (0.00039 mole) of the product of Step A
above in H₂O (25 ml) and CH₃CN (10 ml) was added LiOH
(41 mg, 0.00098 mole). The reaction was stirred at
30 room temperature for 1 hour. The pH was lowered to 3
with TFA and the product was isolated by reverse phase
prep HPLC to yield (after lyophilization) 210 mg of the
title compound as a white solid.

NMR and mass spectrometry were consistent with the
35 desired structure.

- 149 -

Example 37

Preparation of (\pm) β -[[2-[[3-[(aminoiminomethyl)-
5 amino]phenyl]carbonyl]amino]acetyl]amino][1,1'-
biphenyl]-4-propanoic acid, trifluoroacetate salt




20 The above compound was prepared according to the
methodology of Example 2, substituting an equivalent
amount of 4-biphenylcarboxaldehyde for 3-
pyridinecarboxaldehyde in Example 1, Step A.

- 150 -

Example 38

Preparation of (±) ethyl β -[[2-[[3-
 5 (aminoiminomethyl)amino]-5-(trifluoromethyl)-
 phenyl]carbonyl]amino]acetyl]amino]-3,5-
 bis(trifluoromethyl)benzenepropanoate, trifluoroacetate
 salt




The above compound was prepared according to the methodology of Example 1, substituting the equivalent amount of 3,5-bis-trifluoromethylbenzaldehyde (Aldrich) for 3-pyridinecarboxaldehyde in Step A and substituting the equivalent amount of 3-amino-5-trifluoromethylbenzoic acid [which was synthesized by reduction of 3-nitro-5-trifluoromethylbenzoic acid (Lancaster) in ethanol with 10% Pd/C under 50 psi H₂ for 4 hours] for 3-aminobenzoic acid in Step E and stirring the resulting reaction mixture from Step E at reflux overnight instead of 2.5 hours.

NMR and mass spectrometry were consistent with the desired structure.

- 151 -

Example 39

Preparation of (\pm) β -[[2-[[3-[(aminoiminomethyl)-
5 amino]-5-(trifluoromethyl)phenyl]carbonyl]amino]-
5 acetyl]amino]-3,5-bis(trifluoromethyl)benzenepropanoic
acid, trifluoroacetate salt




To 600 mg (0.00082 mole) of the product of Example 38 in 12 ml of H_2O and 12 ml of CH_3CN was added 140 mg (0.0033 mole) of LiOH. The reaction was stirred at room temperature for 1.5 hours. The pH was lowered to 2.5 with TFA and the product isolated by reverse phase prep HPLC to yield (after lyophilization) 520 mg of (\pm) β -[[2-[[3-[(aminoiminomethyl)amino]-5-(trifluoromethyl)phenyl]carbonyl]amino]acetyl]amino]-3,5-bis(trifluoromethyl)benzenepropanoic acid, trifluoroacetate salt as a white solid.

25 NMR and mass spectrometry were consistent with the desired structure.

- 152 -

Example 40**Preparation of 3S-[[2-[[3-(aminocarbonylamino)-phenyl]carbonyl]amino]acetyl]amino]-4-pentyanoic acid**

5



10

Step A

Ethyl 3S-amino-4-pentyanoate hydrochloride was prepared using the method in J. Med. Chem. 1995, 38, 3378-94.

15

Step B

2 g m-aminohippuric acid in 5% aqueous HCl (25 ml) was treated with urea (2 g) and the solution was refluxed for 4 hours. m-N-carbamoylaminohippuric acid was purified by HPLC (RP-CH₃CN/H₂O) and lyophilized to give 1.2 g of white solid. The MS was consistent with the desired product.

Step C

25 A suspension of m-ureahippuric acid (1.2 g) in DMF (5 ml) and pyridine (5 ml) was treated with DSC (1.5 g). A catalytic amount of DMAP was added and the reaction mixture was stirred for 3 hours. A solution of 3S-aminopentanoic acid, hydrochloride (0.8 g) and K₂CO₃ (0.7 g) in saturated aqueous NaHCO₃ (5 ml) was added to the reaction mixture. The resulting mixture was stirred overnight at room temperature. The reaction was diluted to 45 ml with 1:1 CH₃CN:H₂O and acidified with trifluoracetic acid (5 ml). The ester was purified by HPLC (RP-CH₃CN/H₂O) and a white solid (125 mg) was recovered after lyophilization. This material was then treated with 1:1 CH₃CN:H₂O (20


- 153 -

ml) and made basic (pH>12) with LiOH. After complete reaction, the product was purified by HPLC (RP-CH₃CN/H₂O) and the desired product (60 mg) was obtained. MS, ¹H-NMR and CHN analysis were consistent 5 with the desired product.

- 154 -

Example 41

Preparation of (\pm) β -[[2-[[3-[(aminoiminomethyl)-
5 amino]phenyl]carbonyl]amino]acetyl]amino]naphthalene-1-
propanoic acid, trifluoroacetate salt

Step A

15 A mixture of freshly distilled 1-naphthalenecarboxaldehyde (8.6 g), ammonium acetate (10.6 g) and malonic acid (5.7 g) in isopropyl alcohol (50 ml) was refluxed for 4 hours. The reaction was filtered while hot and washed with hot isopropyl
20 alcohol (2 x 50 ml), washed with H₂O (125 ml) and isopropanol (100 ml) and dried in vacuo at 40°C. 4.6 g of β S-aminonaphthalene-1-propanoic acid as a white solid was isolated. MS and ¹H-NMR were consistent with the desired product.

25

Step B

30 A suspension of the product of Step A (4.6 g) in methanol (100 ml) was treated with 4N HCl/dioxane (10 ml). The reaction was stirred overnight and the excess solvent was removed under reduced pressure. The oil was dissolved into 1:1 CH₃CN:H₂O and purified by HPLC (RP-CH₃CN/H₂O). Methyl β S-aminonaphthalene-1-propanoate (4.6 g) as a white solid was obtained. MS and ¹H-NMR were consistent with the desired product.

35

- 155 -

Step C

A suspension of m-guanidinohippuric acid HCl (1.4 g) in DMF (5 ml) and pyridine (5 ml) was treated with DSC (3 g) and a catalytic amount of DMAP. The reaction 5 was stirred overnight at room temperature. The resulting solution was treated with a solution of the product of Step B (1.7 g) and NMM (0.6 ml) in DMF (2.5 ml) and pyridine (2.5 ml). The mixture was stirred overnight at room temperature. The reaction was then 10 treated with TFA and diluted to 50 ml with 1:1 CH₃CN:H₂O. The solution was purified by HPLC (RP-CH₃CN/H₂O) and (\pm) methyl β S-[[2-[[[3- 15 [(aminoiminomethyl)amino]phenyl]carbonyl]amino]acetyl]-amino]naphthalene-1-propanoate (1.3 g) as a white solid was obtained after lyophilization. MS and ¹H-NMR were consistent with the desired product.

Step D

A solution of the product of Step C (0.5 g) in 1:1 20 CH₃CN:H₂O (15 ml) was treated with LiOH until pH > 12. The reaction was monitored by HPLC (RP-CH₃CN/H₂O) and when hydrolysis was complete, the desired material was purified by HPLC (RP-CH₃CN/H₂O). A white solid (0.3 g) was recovered after lyophilization. MS, ¹H-NMR and CHN 25 were consistent with the desired product.


- 156 -

Example 42

Preparation of (±) 3-[[3-[(aminoiminomethyl)amino]-phenyl]carbonyl]amino]-2-oxopyrrolidine-1-propanoic acid, trifluoroacetate salt

5

10

Step A

A solution of *N*-(*tert*-butoxycarbonyl)-L-methionine (6.2 g) in DMF (25 ml) and pyridine (25 ml) was treated with DSC (9.6 g) and a catalytic amount of DMAP. After 4 hours, a solution of β -alanine ethyl ester HCl (3.8 g) and K_2CO_3 (3.5 g) in saturated aqueous $NaHCO_3$ (25 ml) was added. The reaction mixture was stirred overnight at room temperature. The excess solvent was removed under reduced pressure and purified by HPLC (RP-CH₃CN/H₂O). *N*-[2-[[1,1-dimethylethoxy]carbonyl]amino]-4-(methylthio)-1-oxobutyl]- β -alanine, ethyl ester (7.0 g) as a colorless oil was obtained. The oil was confirmed as the desired product by MS and used without further purification.

15

20


25

Step B

6.5 g of the oil from Step A was dissolved in DMF (25 ml) and treated with CH_3I (5.0 ml). After approximately 1 hour, NaH (0.50 g) was added, followed by further addition of NaH (0.50 g). The reaction was treated with H_2O (25 ml) and $EtOAc$ (200 ml). The organic layer was washed with additional H_2O (3 x 25 ml), saturated aqueous $NaCl$ (1 x 25 ml) and dried over $NaSO_4$. The excess solvent was removed under reduced pressure to give 4 g of

30

35



5

as a tan semi-solid. MS was consistent with the structure and the product was used without further purification.

10

Step C

A solution of the product of Step B (4 g) in ethanol (50 ml) was treated with 4N HCl/dioxane (20 ml). The excess solvent was removed under reduced pressure. The crude solid was purified by HPLC (RP-CH₂CN/H₂O). 20% aqueous HCl (10 ml) was added and 1 g of ethyl 3-amino-2-oxopyrrolidine-1-propanoate was obtained as a white solid after lyophilization. MS was consistent with the desired product.

20


Step D

A solution of *m*-guanidinobenzoic acid HCl (0.7 g) in DMF (3 ml) and pyridine (3 ml) was treated with DSC (0.8 g) and a catalytic amount of DMAP. After 3 hours a solution of the product of Step C (0.7 g) in H₂O (3 ml) with an equal molar amount of K₂CO₃ was added. The reaction was stirred overnight at room temperature. The desired ester was isolated by HPLC (RP-CH₃CN/H₂O). The white solid (100 mg) was treated with H₂O (10 ml) and made basic with LiOH (pH>12). After 2 hours, the desired product was isolated by HPLC (RP-CH₃CN/H₂O) and lyophilized. 75 mg of (\pm) 3-[[3-[(aminoiminomethyl)amino]phenyl]carbonyl]amino]-2-oxopyrrolidine-1-propanoic acid, trifluoroacetate salt as a white solid was obtained. MS, ¹H-NMR and CHN analysis were consistent with the desired product.

Example 43

Preparation of 3R-[[2-[[[3-[(aminoiminomethyl)amino]-phenyl]carbonyl]amino]acetyl]amino]-4-pentynoic acid,
5 hydrochloride salt

10



20

Step A

Ethyl 3-(N-(tert-butoxycarbonyl)amino)pent-4-ynoic ester (3 g) [J. Med. Chem., 1995, 38, 3378-94] in CH₂Cl₂ (60 ml) at 0°C was treated with TFA (30 ml). The reaction was stirred for 3 hours. The excess solvent was removed under reduced pressure and a yellow oil (3.3 g) was obtained. The oil was confirmed as the desired product by MS.

Step B

A solution of m-guanidinohippuric acid HCl (3.3 g) in DMF (12 ml) and pyridine (12 ml) was treated with DSC (6.1 g) and a catalytic amount of DMAP. After 3 hours, a solution of crude product (3.3 g) from Step A in saturated aqueous NaHCO₃ (12 ml) was added. The reaction was stirred overnight at room temperature. The excess solvent was removed under reduced pressure. The resulting solid was treated with TFA and 1:1 CH₃CN:H₂O. The product was isolated by HPLC (RP-CH₃CN/H₂O) to yield ethyl 3R-[[2-[[[3-[(aminoiminomethyl)amino]phenyl]carbonyl]amino]acetyl]amino]propynoate trifluoroacetate salt (3 g) as a white solid. MS and ¹H-NMR were consistent with the desired product.

- 159 -

Step C


The product of Step B (3 g) was dissolved in 1:1 CH₃CN:H₂O (50 ml) and treated with LiOH (pH>12). After 4 hours the reaction was acidified with TFA and the TFA salt of the desired product was isolated by HPLC (RP-CH₃CN/H₂O). The lyophilized solid (2.5 g) was slurried with 1:3 CH₃CN:H₂O (100 ml) and ion exchange resin, AG 2-X8 chloride form (BioRad) (50 g). The mixture was filtered and treated with 20% HCl (5 ml). The clear solution was lyophilized and the resin exchange process was repeated. The desired product (2.2 g) was obtained. MS, ¹H-NMR and CHNCl were consistent with the desired product.

- 160 -

Example 44

Preparation of 3S-[[2-[[3-[[[(phenylmethyl)amino]-5
carbonyl]amino]phenyl]carbonyl]amino]acetyl]amino]-4-
pentynoic acid

10



15

Step A
 α -Aminohippuric acid HCl (20 g) in CH_3CN (100 ml) was treated with benzyl isocyanate (16 ml). The reaction was treated with 5% aqueous HCl (400 ml), filtered and washed with H_2O (50 ml) to give 21 g of α -(benzylurea)hippuric acid. The MS and $^1\text{H-NMR}$ were consistent with the desired product. No further purification was done.

20

Step B

Ethyl 3S-[[2-[[3-[[[(phenylmethyl)amino]-carbonyl]amino]phenyl]carbonyl]amino]acetyl]amino]-4-pentynoate was prepared using the method in Example 40 substituting an equal molar amount of α -(benzylurea)hippuric acid for α -ureahippuric acid. The desired ester was purified by HPLC (RP - $\text{CH}_3\text{CN}/\text{H}_2\text{O}$) to give 1.2 g as a white solid. The MS and $^1\text{H-NMR}$ were consistent with the desired ester.

30

Step C


A solution of ethyl 3S-[[2-[[3-[[[(phenylmethyl)-amino]carbonyl]amino]phenyl]carbonyl]amino]acetyl]-amino]-4-pentynoate (1.0 g) in 1:1 $\text{CH}_3\text{CN}:\text{H}_2\text{O}$ (20 ml) was treated with KOH (pH>12). After 4 hours the reaction was acidified with TFA and purified twice by HPLC (RP- $\text{CH}_3\text{CN}/\text{H}_2\text{O}$). A white solid (300 mg) was obtained. MS, $^1\text{H-NMR}$ and CHN were consistent with the desired product.

- 161 -

Example 45

Preparation of 3S-[[2-[[3-[(aminoiminomethyl)amino]-
5 phenyl]carbonyl]amino]acetyl]amino]-4-pentyoic acid,
hydrochloride salt

10



15 The product of Example 58 (6 g) was dissolved in 1:1 CH₃CN:H₂O (75 ml) and treated with KOH. The pH was maintained greater than 12 by addition of KOH. After 4 hours the reaction was acidified with TFA and purified by HPLC (RP-CH₃CN/H₂O). The TFA salt (4.2 g) was obtained after the appropriate fractions were lyophilized. The solid was slurried in 1:1 CH₃CN:H₂O (100 ml) and treated with ion exchange resin AG 2-X8 chloride form (BioRad) (50 g). The mixture was filtered and treated with 20% HCl (5 ml). After lyophilization the resin exchange was repeated. The desired product as the HCl salt (3.5 g) was obtained.


20 25 MS, ¹H-NMR and CHNCl were consistent with the desired product.

- 162 -

Example 46

Preparation of β -[[2-[[3-(aminocarbonylamino)phenyl]-carbonyl]amino]acetyl]amino]pyridine-3-propanoic acid,
5 hydrochloride salt

10




15 Urea (4 g) and ethyl β -[[2-[(3-aminophenyl)-carbonyl]amino]acetyl]amino]pyridine-3-propanoate trifluoroacetate salt (4 g) were dissolved in 20% aqueous HCl (50 ml) and refluxed for 6 hours. The reaction was made basic with KOH (pH>12). After 4
20 hours the reaction was acidified with TFA and purified by HPLC (RP-CH₃CN/H₂O). The white solid was dissolved in 1:1 CH₃CN:H₂O (100 ml) and subjected to the resin exchange described in Example 43, Step C. Lyophilization gave the desired product (3.2 g). MS,
25 ¹H-NMR and CHNCl were consistent with the desired product.

- 163 -

Example 47

Preparation of (\pm) β -[[2-[[3-[[[(phenylmethyl)amino]-carbonyl]amino]phenyl]carbonyl]amino]acetyl]amino]-pyridine-3-propanoic acid, hydrochloride salt




The product of Example 48 (5 g) was dissolved in 1:1 CH₃CN:H₂O (75 ml) and treated with KOH. The pH was maintained greater than 12 by addition of KOH. After 4 hours the reaction was acidified with TFA and purified by HPLC (RP-CH₃CN/H₂O). The TFA salt (4.5 g) was obtained after lyophilization. The solid was slurried in 1:1 CH₃CN:H₂O (100 ml) and ion exchange resin, AG 2-X8 chloride form (BioRad) (50 g). The mixture was filtered and treated with 20% HCl (5 ml). After lyophilization the resin exchange process was repeated. The desired product (4.1 g) was obtained as a white solid. MS, ¹H-NMR and CHNCl were consistent with the desired product.

30

- 164 -

Example 48

Preparation of (\pm) ethyl β -[[2-[[3-[[[(phenylmethyl)-
5 amino]carbonyl]amino]phenyl]carbonyl]amino]acetyl]-
amino]pyridine-3-propanoate, hydrochloride salt

Step A

15 A solution of α -nitrohippuric acid (5.6 g) in DMF (25 ml) was treated with DSC (9.6 g) and a catalytic amount of DMAP. After 5 hours, a solution of ethyl 3-amino-3-(3-pyridyl)propanoate 2HCl (8 g) and K_2CO_3 (2 g) in saturated aqueous $NaHCO_3$ (25 ml) was added. The reaction mixture was stirred overnight at room
20 temperature. H_2O (25 ml) was added and the mixture was filtered. The resulting solid was washed with H_2O (25 ml), slurried with CH_3CN (25 ml) and filtered. Ethyl β -[[2-[[3-
25 nitrophenyl]carbonyl]amino]acetyl]amino]pyridine-3-
propanoate (6.5 g) was obtained as a white solid. MS was consistent with the desired product.

Step B

30 A suspension of the product of Step A (6.5 g) and 5% Pd/C (0.6 g) in H_2O (50 ml) and ethanol (50 ml) was subjected to 50 psi H_2 for 3 hours. The mixture was filtered through a celite pad and the excess solvent was removed under reduced pressure. The resulting oil was treated with CH_2Cl_2 , and the solvent was again
35 removed under reduced pressure. Ethyl β -[[2-[[3-aminophenyl]carbonyl]amino]acetyl]amino]pyridine-3-

- 165 -


propanoate (5.8 g) was recovered as a tan foam. MS and ¹H-NMR were consistent with the desired product.

Step C

5 A solution of the product of Step B (1.9 g) in CH₃CN (5 ml) was treated with benzyl isocyanate (0.8 ml). After 1 hour benzyl isocyanate (0.1 ml) was added to complete the reaction. After 0.25 hour the reaction was treated with H₂O (50 ml). The resulting viscous oil
10 was dissolved in CH₃CN and was acidified with TFA. The solution was purified by HPLC (RP-CH₃CN/H₂O) and lyophilized. The white solid was repurified by HPLC (RP-CH₃CN/H₂O) and treated with 20% HCl (5 ml). The desired product (1.3 g) was obtained as a white solid.
15 MS, ¹H-NMR and CHNCL were consistent with the desired product.

Example 51

Preparation of (\pm)ethyl β -[[2-[[3-[(aminoiminomethyl)-
15 amino]phenyl]carbonyl]amino]acetyl]amino]furan-3-
5 propanoate, trifluoroacetate salt

Step A

A suspension of 3-furancarboxaldehyde (8.6 ml), malonic acid monoethyl ester (15.8 g) and ammonium acetate (9.6 g) in isopropyl alcohol (200 ml) was heated to reflux under nitrogen. After 5 hours, the excess solvent was removed under reduced pressure and the semi-solid was treated with H_2O (250 ml) and acidified to pH 2 using 12N HCl. The aqueous layer was washed with CH_2Cl_2 (2 x 100 ml). The aqueous layer was neutralized to pH >9 with K_2CO_3 . The product was extracted with CH_2Cl_2 (2 x 100 ml). The organic layer was dried over Na_2SO_4 and the excess solvent was removed under reduced pressure to give ethyl β -aminofuran-3-propanoate (5 g) as a golden oil. The MS and 1H -NMR were consistent with the desired product.

Step B


30 A solution of m -guanidinohippuric acid HCl (1.4 g) in DMF (5 ml) and pyridine (5 ml) was treated with DSC (1.9 g) and a catalytic amount of DMAP. After 5 hours, to a solution of the product of Step A (1.2 g) in CH_3CN (1 ml) was added saturated aqueous $NaHCO_3$ (1 ml). The mixture was stirred overnight at room temperature and 35 purified by HPLC (RP- CH_3CN/H_2O). The lyophilized solid (1.2 g) had MS, 1H -NMR and CHN analysis that were consistent with the desired product.

- 167 -

Example 52

Preparation of (\pm) β -[[2-[[3-[(aminoiminomethyl)-
15 amino]phenyl]carbonyl]amino]acetyl]amino]furan-3-
5 propanoic acid, trifluoroacetate salt

10




The product of Example 51 (0.6 g) was dissolved in
1:1 CH₃CN:H₂O (15 ml) and was treated with NaOH (pH>12).
15 After 4 hours the reaction was acidified with TFA and
purified by HPLC (RP-CH₃CN/H₂O). The lyophilized solid
(0.3 g) had MS, ¹H-NMR and CHN analysis that were
consistent with the desired product.

Example 53

Preparation of 3-[[2-[[3-[(aminoiminomethyl)amino]phenyl]carbonyl]amino]acetyl]amino]pentanedioic acid,
5 trifluoroacetate salt

10

Step A

Dimethyl 3-ketoglutarate (13 g) in methanol (50 ml) was treated with ammonium formate (5 g) and NaCNBH₃ (2 g). 10 ml of H₂O was added and the excess solvent removed under reduced pressure. The semi-solid was dissolved in 5% aqueous HCl (250 ml), and washed with CH₂Cl₂ (2 x 50 ml). The aqueous layer was made basic (pH>9) with K₂CO₃, and the product was extracted using CH₂Cl₂ (2 x 75 ml). The organic layers were combined and dried with Na₂SO₄. The excess solvent was removed to give 2.5 g of the dimethyl (±)3-aminoglutarate. This was dissolved in methanol (50 ml) and treated with 4N HCl/Dioxane (10 ml). The excess solvent was removed under reduced pressure to give a 2.7 g of dimethyl (±)3-aminoglutarate hydrochloride. MS and ¹H-NMR were consistent with the desired product.

Step B

30 A solution of *m*-guanidinohippuric acid HCl (1.5 g) in DMF (4.5 ml) and pyridine (4.5 ml) was treated with DSC (1.8 g) and a catalytic amount of DMAP. After 2 hours, a solution of dimethyl 3-aminoglutarate HCl (1.1 g) and NMM (350 μ l) in H₂O (3 ml) was added to the reaction. The reaction was stirred overnight at room temperature and the product was isolated by HPLC. 1.5 g of 3-[[2-[[3-[(aminoiminomethyl)amino]phenyl]-

- 169 -

carbonyl]amino]acetyl]amino]pentanedioic acid, bismethyl ester was obtained as a white solid. MS and ¹H-NMR were consistent with the desired product.

5 Step C


The product of Step B (750 mg) was dissolved in 1:1 CH₃CN:H₂O (40 ml) and treated with KOH (pH>12). After 4 hours, the reaction was acidified with TFA and purified by HPLC (RP-CH₃CN/H₂O). The lyophilized solid 10 (400 mg) had MS, ¹H-NMR and CHN analysis that were consistent with the desired product.

- 170 -

Example 54

Preparation of (\pm) hydrogen methyl 3-[[2-[[[3-
5 ((aminoiminomethyl)amino]phenyl]carbonyl]amino]acetyl]-
amino]pentanedioate, trifluoroacetate salt

10

Step A

15 A solution of *m*-guanidinohippuric acid HCl (1.5 g) in DMF (4.5 ml) and pyridine (4.5 ml) was treated with DSC (1.8 g) and a catalytic amount of DMAP. After 2 hours, a solution of dimethyl 3-aminoglutarate HCl (1.1 g) and NMM (350 μ l) in H_2O (3 ml) was added to the reaction. The reaction was stirred overnight at room temperature and the product was isolated by HPLC. 3-
20 [[2-[[[3-((aminoiminomethyl)amino]phenyl]carbonyl]amino]acetyl]amino]pentanedioic acid, bis methyl ester (1.5 g) as a white solid was obtained. MS and 1H -NMR were consistent with the desired product.

25 Step B


750 mg of the product of Step A was dissolved in Na_2PO_4 buffer (50 ml, 50 mM, pH 8.5) and treated with porcine esterase (200 μ l). The pH was adjusted using LiOH. After 48 hours, the solution was acidified with TFA and purified by HPLC (RP-CH₃CN/ H_2O). The lyophilized solid (175 mg) had MS, 1H -NMR and CHN analysis consistent with the desired product.

- 171 -

Example 55

Preparation of (\pm) β -[[2-[[3-[(aminoiminomethyl)-
15 amino]phenyl]carbonyl]amino]acetyl]amino]furan-2-
5 propanoic acid, trifluoroacetate salt

10



Step A

A suspension of 2-furancarboxaldehyde (4.8 g),
15 ammonium acetate (9.6 g) and malonic acid monoethyl
ester (6.6 g) in isopropanol (50 ml) was refluxed for 6
hours. The excess solvent was removed under reduced
pressure and the resulting oil was treated with ethyl
acetate (100 ml) and 5% aqueous HCl (400 ml). The
20 aqueous layer was then washed with ethyl acetate (100
ml). The aqueous layer was made basic with K_2CO_3 (pH
9). The product was extracted with CH_2Cl_2 (2 x 100 ml).
The organic layers were combined and dried with Na_2SO_4
and the excess solvent was removed. Ethyl β -
25 aminofuran-2-propanoate (2.5 g) as a dark oil was
recovered. MS and 1H -NMR were consistent with the
desired product. The dark oil was treated as described
in Example 53, Step A to give 2.7 g of ethyl β -
aminofuran-2-propanoate hydrochloride.

30

Step B

A solution of m -guanidinohippuric acid HCl (272
mg) in DMF (1 ml) and pyridine (1 ml) was treated with
DSC (450 mg) and a catalytic amount of DMAP. After 2
35 hours, a solution of the product of Step A (221 mg),
NMM (111 μ l) in H_2O (1 ml) and CH_3CN (1 ml) was added.
The reaction was stirred overnight at room temperature.

- 172 -

(±) Ethyl β -[[2-[[3-[(aminoiminomethyl)-
amino]phenyl]carbonyl]amino]acetyl]amino]furan-2-
propanoate was purified by HPLC (RP-CH₃CN/H₂O) and
lyophilized to give a white solid (200 mg). MS was
5 consistent with the desired product.


Step C

The product of Step B (200 mg) was dissolved in
1:1 CH₃CN:H₂O (20 ml) and treated with LiOH (pH>12).
10 After 4 hours, the reaction was acidified with TFA and
purified by HPLC (RP-CH₃CN/H₂O). The lyophilized solid
(175 mg) had MS, ¹H-NMR and CHN analysis that were
consistent with the desired product.

- 173 -

Example 56

Preparation of (\pm) β -[[2-[[3-[(aminoiminomethyl)-
5 amino]phenyl]carbonyl]amino]acetyl]amino]naphthalene-2-
propanoic acid, trifluoroacetate salt

Step A

15 A suspension of 2-naphthaldehyde (7.8 g) and ammonium acetate (9.6 g) in isopropyl alcohol (50 ml) was heated for 1 hour at reflux. Malonic acid (5.2 g) was added and reflux was continued for 3 hours. The reaction was filtered while hot and the solid washed 20 with hot isopropyl alcohol (50 ml) followed by CH_3CN (100 ml). The white solid was dried overnight in vacuo and β -aminonaphthalene-2-propanoic acid (9 g) was recovered. MS and $^1\text{H-NMR}$ were consistent with the structure.

25

Step B

30 A suspension of the product of Step A (2.5 g) in methanol (100 ml) was treated with 4N HCl/dioxane (10 ml). The resulting solution was stirred overnight. The excess solvent was removed under reduced pressure and the semi solid was purified by HPLC (RP- $\text{CH}_3\text{CN}/\text{H}_2\text{O}$). The solid was dissolved in $\text{CH}_3\text{CN}/\text{H}_2\text{O}$, treated with 20% aqueous HCl (5 ml) and lyophilized to give methyl β -aminonaphthalene-2-propanoate hydrochloride (1.1 g). 35 MS and $^1\text{H-NMR}$ were consistent with the structure.

- 174 -

Step C

A solution of *m*-guanidinohippuric acid (0.7 g) in DMF (4 ml) and pyridine (4 ml) was treated with DSC (1.1 g) and a catalytic amount of DMAP. After 4 hours, 5 a solution of the product of Step B (0.9 g), NMM (0.4 ml) in DMF (2 ml), pyridine (2 ml) and H₂O (1 ml) were added. The reaction was stirred overnight at room temperature and acidified with TFA. The desired product was isolated by HPLC (RP-CH₃CN/H₂O). The 10 lyophilized solid (0.7 g) had MS, ¹H-NMR and CHN analysis that were consistent with the desired product.


Step D

The product of Step C (200 mg) was dissolved in 15 1:1 CH₃CN:H₂O (20 ml) and treated with KOH (pH>12). After 4 hours, the reaction was acidified with TFA and purified by HPLC (RP-CH₃CN/H₂O). The lyophilized solid (175 mg) had MS, ¹H-NMR and CHN analysis that were consistent with the desired product.

- 175 -

Example 57

Preparation of (\pm) methyl β -[[2-[[3-
[(aminoiminomethyl)amino]phenyl]carbonyl]amino]acetyl]-
5 amino]thiophene-3-propanoate, trifluoroacetate salt

Step A

15 A solution of 3-thiophenecarboxaldehyde (11.2 g) in isopropanol (100 ml) was treated with ammonium acetate (20 g). The resulting mixture was heated and malonic acid (10.4 g) was added. The reaction was refluxed for 4 hours and filtered while hot. The solid was washed with hot isopropanol (2 x 50 ml) and dried
20 in vacuo overnight at 40°C. 8 g of β -aminothiophene-3-propanoic acid was recovered. MS and $^1\text{H-NMR}$ were consistent with the desired product.

Step B

25 A suspension of the product of Step A (5 g) in methanol (100 ml) was treated with 4N HCl/dioxane (10 ml). The reaction was stirred overnight. The excess solvent was removed under reduced pressure. Methyl β -aminothiophene-3-propanoate hydrochloride (7.8 g) was
30 isolated as a yellow foam. MS and $^1\text{H-NMR}$ were consistent with the desired product.

Step C

35 A solution of m -guanidinohippuric acid HCl (2.7 g) in DMF (10 ml) and pyridine (10 ml) was treated with DSC (4.5 g) and a catalytic amount of DMAP. After 4 hours, a solution of the product of Step B (2.2 g) and

- 176 -


NMM (1.3 ml) in DMF (5 ml) was added and the reaction was stirred overnight at room temperature. The reaction mixture was treated with 1:1 CH₃CN:H₂O (50 ml) and acidified with TFA. The desired compound was 5 isolated by HPLC (RP-CH₃CN/H₂O). The lyophilized solid (2.2 g) had MS, ¹H-NMR and CHN analysis that were consistent with the desired product.

- 177 -

Example 58

Preparation of ethyl 3S-[[2-[[3-[(aminoiminomethyl)-
15 amino]phenyl]carbonyl]amino]acetyl]amino]-4-pentyoate,
5 trifluoroacetate salt

10



.TFA

A solution of m-guanidinohippuric acid HCl (2.7 g)
15 in DMF (10 ml) and pyridine (10 ml) was treated with
DSC (4.5 g) and a catalytic amount of DMAP. After 4
hours, a solution of ethyl 3S-amino-4-pentyoic acid,
hydrochloride (1.8 g) and NMM (1.1 ml) in DMF (5 ml)
was added and the reaction was stirred overnight at
20 room temperature. The reaction mixture was treated
with 1:1 CH₃CN:H₂O (50 ml) and acidified with TFA. The
desired compound was isolated by HPLC (RP-CH₃CN/H₂O).
The lyophilized solid (2.6 g) had MS, ¹H-NMR and CHN
analysis that were consistent with the desired product.


25

- 178 -

Example 59

Preparation of (\pm) β -[[2-[[3-[(aminoiminomethyl)-
5 amino]phenyl]carbonyl]amino]acetyl]amino]thiophene-3-
propanoic acid, trifluoroacetate salt

10




15 The product of Example 57 (750 mg) was dissolved in 1:1 CH₃CN:H₂O (20 ml) and treated with KOH (pH>12). After 4 hours, the reaction was acidified with TFA and purified by HPLC (RP-CH₃CN/H₂O). The lyophilized solid (500 mg) had MS, ¹H-NMR and CHN analysis that were consistent with the desired product.

20

- 179 -

Example 60

Preparation of (\pm) 2-[3-[[2-[[3-[(aminoiminomethyl)-amino]phenyl]carbonyl]amino]acetyl]amino]-4-carboxybutylsulfonylbenzoic acid, trifluoroacetate salt

15 Step A

A solution of 2-[(3-amino-4-carboxybutyl)thio]-benzoic acid (1 g) (prepared according to U.S. 5,409,939) in methanol (50 ml) was treated with 4N HCl/dioxane (10 ml) overnight. The excess solvent was 20 removed under reduced pressure to give the desired product (0.9 g). MS of the white solid, methyl 2-[(3-amino-4-(methoxycarbonyl)butyl]thio]benzoate was consistent with the proposed structure.

25 Step B

A solution of m-guanidinohippuric acid HCl (0.8 g) in DMF (3 ml) and pyridine (3 ml) was treated with DSC (1.2 g) and a catalytic amount of DMAP. After 2 hours, a solution of the product of Step A (1 g), NMM (0.3 ml) 30 in DMF (3 ml) was added. The reaction was stirred overnight at room temperature. KOH was added until pH greater than 12. After 4 hours, the reaction was acidified and purified by HPLC (RP-CH₃CN/H₂O). The lyophilized solid, (\pm) 2-[3-[[2-[[3-[(aminoiminomethyl)amino]phenyl]carbonyl]amino]acetyl]-35 amino]-4-carboxybutylthio]benzoic acid,

- 180 -

trifluoroacetate salt (750 mg) had MS, ¹H-NMR and CHN analysis that were consistent with the desired product.

Step C


5 A solution of the product of Step B (320 mg) in 1:1 CH₃CN:H₂O (50 ml) was treated with m-chloroperoxybenzoic acid (340 mg). The reaction was stirred overnight at room temperature and purified by HPLC (RP-CH₃CN/H₂O). The lyophilized solid (300 mg) had
10 MS, ¹H-NMR and CHN analysis that were consistent with the desired product.

- 181 -

Example 61

Preparation of (\pm) β -[[2-[[3-[(aminoiminomethyl)-
5 amino]phenyl]carbonyl]amino]acetyl]amino]thiophene-2-
propanoic acid, trifluoroacetate salt

10

Step A

15 A solution of 3-amino-3-(2-thienyl)propanoic acid (0.5 g) [prepared substituting a molar equivalent amount of 2-thiophene-carboxaldehyde in Example 57, Step A] in methanol (50 ml) was treated with 4N HCl/dioxane (10 ml). After 6 hours the excess solvent was removed under reduced pressure to give a waxy 20 solid. Treatment with $\text{Et}_2\text{O}/\text{CH}_3\text{CN}$ produced methyl β -aminothiophene-2-propanoate (370 mg) as a white powder. MS and $^1\text{H-NMR}$ were consistent with the desired product.


Step B

25 A solution of m-guanidinohippuric acid HCl (0.4 g) in DMF (1.5 ml) and pyridine (1.5 ml) was treated with DSC (0.6 g) and a catalytic amount of DMAP. After 3 hours, a solution of the product of Step A (0.3 g) and NMM (220 μl) in DMF (1.5 ml) was added. The reaction 30 was stirred overnight at room temperature. The ester was isolated by HPLC (RP- $\text{CH}_3\text{CN}/\text{H}_2\text{O}$) and lyophilized. The resulting white solid was treated with KOH ($\text{pH}>12$) in 1:4 $\text{CH}_3\text{CN}:\text{H}_2\text{O}$. After 4 hours, the reaction was acidified by TFA and purified by HPLC (RP- $\text{CH}_3\text{CN}/\text{H}_2\text{O}$). 35 The lyophilized solid (300 mg) had MS, $^1\text{H-NMR}$ and CHN analysis that were consistent with the desired product.

- 182 -

Example 62

Preparation of (\pm) methyl 2-[[3-[2-[[[3-
[(aminoiminomethyl)amino]phenyl]carbonyl]amino]acetyl]-
5 amino]-4-carboxybutyl]thio]benzoate, trifluoroacetate
salt




15 A solution of *m*-guanidinohippuric acid HCl (0.8 g) in DMF (3 ml) and pyridine (3 ml) was treated with DSC (1.2 g) and a catalytic amount of DMAP. After 2 hours, a solution of methyl 2-[[3-amino-4-(methoxycarbonyl)-butyl]thio]benzoate (1 g) [prepared according to U.S. 5,409,939], NMM (0.3 ml) in DMF (3 ml) was added. The reaction was stirred overnight at room temperature. KOH was added until the pH was greater than 12. After 2 hours, the reaction was acidified and purified by HPLC (RP-CH₃CN/H₂O). The lyophilized solid, (250 mg) 20 had MS, ¹H-NMR and CHN analysis that were consistent with the desired product.

25

- 183 -

Example 63

Preparation of (\pm) methyl 3-[[2-[[3-
[(aminoiminomethyl)amino]phenyl]carbonyl]amino]acetyl]-
5 amino]-5-[(4-methylphenyl)thio]pentanoate,
trifluoroacetate salt



Step A

15 A solution of 3-amino-5-[(4-methylphenyl)-thio]pentanoic acid (1.0 g) [prepared according to U.S. 5,409,939] in methanol (50 ml) was treated with 4N HCl/dioxane (10 ml). The reaction was stirred overnight at room temperature. The excess solvent was removed under reduced pressure. Methyl 3-amino-5-[(4-methylphenyl)thio]pentanoate (1.1 g) as a white solid was obtained. MS and ¹H-NMR were consistent with the desired product.


25 Step B

25 A solution of *m*-guanidinohippuric acid HCl (0.6 g) in DMF (2 ml) and pyridine (2 ml) was treated with DSC (0.7 g) and a catalytic amount of DMAP. After 1 hour, a solution of the product of Step A (0.6 g) in 30 saturated aqueous NaHCO₃ (1.5 ml) and acetonitrile (1.5 ml) was added. The reaction was stirred for 2 hours at room temperature. The reaction was acidified with TFA and the title compound (0.6 g) was isolated by HPLC as a white solid. MS and ¹H-NMR were consistent with the 35 desired product.


- 184 -

Example 64

Preparation of (±) methyl 3-[[2-[[[3-
 5 [(aminoiminomethyl)amino]phenyl]carbonyl]amino]acetyl]-
 amino]-4-[[[(4-methylphenyl)sulfonyl]amino]butanoate,
 trifluoroacetate salt

Step A

15 A mixture of aminoacetaldehyde dimethyl acetal (15.8 g), p-toluenesulfonylchloride (19.1 g) and Et₃N (10.1 g) in CH₂Cl₂ (200 ml) was stirred for 2 hours.
 The reaction was treated with 5% aqueous HCl (50 ml) and Et₂O (200 ml). The layers were separated and the organic layer was washed with 5% aqueous HCl (50 ml), H₂O (50 ml) and dried over Na₂SO₄. The excess solvent was removed under reduced pressure to give 30 g of the desired acetal;


confirmed by MS and ¹H-NMR.

25

Step B

30 A mixture of the acetal from Step A (10 g), CH₃CN (70 ml) and aqueous HCl (15 ml) was heated to 50°C for 10 minutes. Diethylether was added and the desired aldehyde was extracted. The aldehyde was then used without further purification. The desired aldehyde

was verified by MS.




35

- 185 -

Step C

5 A mixture of ethyldiazoacetate (2.3 g), SnCl_2 (2.5 g) in CH_2Cl_2 (75 ml) was treated with the aldehyde from Step B (5 g). After 2 hours, aqueous HCl and Et_2O were added. The organic layer was separated and dried with MgSO_4 . The solvent was removed under reduced pressure to yield 5 g of crude β -keto ester



; confirmed by MS and $^1\text{H-NMR}$ and


used without further purification.

10

Step D

15 The β -keto ester from Step C (12 g), methanol (100 ml), $\text{H}_4\text{N}^+ \text{HCO}_2^-$ (30 g) and NaCNBH_3 (1.3 g) was stirred. After 24 hours, the excess solvent was removed under reduced pressure. The resulting semi-solid was treated with CH_2Cl_2 and the desired product was extracted using aqueous HCl. Removal of the solvent gave 6 g of crude

β -amino ester



; confirmed by MS

and $^1\text{H-NMR}$.

20

Step E


25 A solution of *m*-guanidinohippuric acid HCl (337 mg) in DMF (1 ml) and pyridine (1 ml) was treated with DSC (0.4 g) and a catalytic amount of DMAP. After 2 hours, a solution of the product of Step D (322 mg) and NMM (220 μ l) in DMF (1 ml) was added. The reaction was stirred overnight at room temperature. The reaction was acidified with TFA and the title compound (250 mg) was isolated by HPLC (RP- $\text{CH}_3\text{CN}/\text{H}_2\text{O}$) as a white solid.

30 MS, CHN and $^1\text{H-NMR}$ were consistent with the desired product.

- 186 -

Example 65

Preparation of 3-[[2-[[3-[(aminoiminomethyl)amino]-
5 phenyl]carbonyl]amino]acetyl]amino]-4-[(4-
methylphenyl)sulfonyl]amino]butanoic acid,
trifluoroacetate salt




15 A solution of the product of Example 64 (180 mg) in 1:1 CH₃CN:H₂O (4 ml) was treated with LiOH (100 mg). After 2 hours, the reaction was acidified with TFA and purified by HPLC (RP-CH₃CN/H₂O). The title compound (100 mg) was isolated as a white solid. MS, ¹H-NMR and
20 CHN analysis were consistent with the desired product.

- 187 -

Example 66

Preparation of (\pm) 3-[[2-[[3-[(aminoiminomethyl)amino]-phenyl]carbonyl]amino]acetyl]amino]-5-[(4-methylphenyl)thio]pentanoic acid, trifluoroacetate salt



15 A solution of 180 mg of the product from Example 63 in 1:1 CH₃CN:H₂O (4 ml) was treated with LiOH (100 mg). After 2 hours, the reaction was acidified with TFA and purified by HPLC (RP-CH₃CN/H₂O). 3-[[2-[[3-[(aminoiminomethyl)amino]phenyl]carbonyl]amino]acetyl]amino]-5-[(4-methylphenyl)thio]pentanoic acid, trifluoroacetate salt (100 mg) was isolated as a white solid. MS, ¹H-NMR and CHN analysis were consistent with the desired product.


20

- 188 -

Example 67

Preparation of (\pm)3-[[2-[[3-[(aminoiminomethyl)amino]-phenyl]carbonyl]amino]acetyl]amino]-5-[(4-methylphenyl)sulfonyl]pentanoic acid, trifluoroacetate salt

10




15 A solution of the product from Example 63 (200 mg) in 1:1 CH₃CN:H₂O (4 ml) was treated with of m-chloroperoxybenzoic acid (460 mg). The reaction was stirred overnight at room temperature. The reaction was treated with LiOH (200 mg). After 2 hours, the 20 reaction was acidified with TFA and purified by HPLC (RP-CH₃CN/H₂O). 3-[[2-[[3-[(aminoiminomethyl)amino]-phenyl]carbonyl]amino]acetyl]amino]-5-[(4-methylphenyl)sulfonyl]pentanoic acid, trifluoroacetate salt (180 mg) was isolated as a white solid. MS, ¹H-NMR 25 and CHN analysis were consistent with the desired product.

- 189 -

Example 68

Preparation of 3S-[[2-[[[3-[(aminoiminomethyl)amino]-phenyl]carbonyl]amino]acetyl]amino]-4-(phenylthio)butanoic acid, trifluoroacetate salt

Step A

15 A suspension of phenylmethyl 3S-[[{(1,1-dimethylethoxy)carbonyl]amino}-4-[(methylsulfonyl)-oxy]butanoate (3.9 g) [prepared according to U.S. 5,409,939], thiophenol (1.1 ml) and K_2CO_3 (1.4 g) in DMF (20 ml) was stirred at room temperature overnight. The 20 reaction was treated with ethyl acetate and the organic layer was washed with H_2O (2 x 25 ml) and saturated NaCl (25 ml). The organic layer was dried with Na_2SO_4 and the excess solvent removed under reduced pressure to give a golden oil (4.5 g). The oil was dissolved in 25 CH_2Cl_2 (100 ml) and treated with TFA (20 ml). After 4 hours the excess solvent was removed under reduced pressure and the product was purified by HPLC (RP- CH_3CN/H_2O). Phenylmethyl 3S-amino-4-(phenylthio)butanoate TFA salt (1.2 g) was isolated as 30 a white solid. MS and 1H -NMR were consistent with the desired product.

Step B

35 A solution of α -guanidinohippuric acid HCl (273 mg) and NMM (110 μ l) in DMF (1 ml) was treated with pivaoyl chloride (120 μ l). After 30 minutes, a solution of the product from Step A (208 mg), NMM (110

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/13500

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 6	C07D213/55	A61K31/44	C07C279/18	A61K31/155
	C07D405/10	A61K31/395	C07D223/12	C07D401/14
	C07C275/28	A61K31/17	C07D401/10	C07D317/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 445 796 A (F.HOFFMANN-LA ROCHE) 11 September 1991 see page 7, line 37 - line 40; claim 1 ---	1-58
E	WO 96 26190 A (SMITHKLINE BEECHAM) 29 August 1996 see claim 1 ---	1-58
P,A	WO 96 00574 A (SMITHKLINE BEECHAM) 11 January 1996 see claim 1 ---	1-58
A	EP 0 643 072 A (TAKEDA) 15 March 1995 see claim 1 ---	1-58
A	WO 94 18981 A (MERCK & CO.) 1 September 1994 see page 28, line 22; claim 1 -----	1-58

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

10 December 1996

Date of mailing of the international search report

23.01.1997

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl
Fax (+ 31-70) 340-3016

Authorized officer

Gettins, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/13500

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-445796	11-09-91	CA-A- 2037153 IL-A- 97401 JP-B- 2501252 JP-A- 4217652 US-A- 5430024 US-A- 5273982 HR-A- 930353		10-09-91 15-03-95 29-05-96 07-08-92 04-07-95 28-12-93 30-06-96
WO-A-9626190	29-08-96	NONE		
WO-A-9600574	11-01-96	AU-A- 3001095 WO-A- 9600730		25-01-96 11-01-96
EP-A-643072	15-03-95	AU-A- 6477194 CA-A- 2126026 CN-A- 1098409 FI-A- 942881 HU-A- 70045 JP-A- 7157472 NO-A- 942274 US-A- 5550131		22-12-94 18-12-94 08-02-95 18-12-94 28-09-95 20-06-95 19-12-94 27-08-96
WO-A-9418981	01-09-94	AU-A- 6246594 BG-A- 99863 CA-A- 2155123 CN-A- 1118139 CZ-A- 9502108 EP-A- 0684823 FI-A- 953916 HU-A- 71796 JP-T- 8507072 NO-A- 953270 PL-A- 310386		14-09-94 29-02-96 01-09-94 06-03-96 14-02-96 06-12-95 21-08-95 28-02-96 30-07-96 19-10-95 11-12-95

AN 1997:290093 CAPLUS
 DN 126:264011
 TI Preparation of meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
 IN Ruminski, Peter Gerrard; Clare, Michael; Collins, Paul Waddell; Desai, Bipinchandra Nanubhai; Lindmark, Richard John; Rico, Joseph Gerace; Rogers, Thomas Edward; Russell, Mark Andrew; et al.
 PA G.D. Searle & Co., USA; Ruminski, Peter Gerrard; Clare, Michael; Collins, Paul Waddell; Desai, Bipinchandra Nanubhai; Lindmark, Richard, John
 SO PCT Int. Appl., 930 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9708145	A1	19970306	WO 1996-US13500	19960827
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
	CA 2230209	AA	19970306	CA 1996-2230209	19960827
	AU 9671039	A1	19970319	AU 1996-71039	19960827
	AU 702487	B2	19990225		
	EP 850221	A1	19980701	EP 1996-932142	19960827
	EP 850221	B1	20010718		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1201454	A	19981209	CN 1996-197911	19960827
	CN 1085980	B	20020605		
	BR 9610422	A	19990713	BR 1996-10422	19960827
	JP 11510814	T2	19990921	JP 1996-510397	19960827
	IL 123164	A1	20010319	IL 1996-123164	19960827
	AT 203234	E	20010815	AT 1996-932142	19960827
	ES 2161373	T3	20011201	ES 1996-932142	19960827
	RU 2196769	C2	20030120	RU 1998-105408	19960827
	NO 9800817	A	19980424	NO 1998-817	19980226
	HK 1021532	A1	20020208	HK 1998-114666	19981228
PRAI	US 1995-3277P	P	19950830		
	WO 1996-US13500	W	19960827		
OS	MARPAT 126:264011				
AB	The title compds. I [A = (un)substituted ureido, guanidino, etc. (generic structures given); Z1 = H, alkyl, OH, alkoxy, halo, (di)(alkyl)amino, aryl, etc.; V = NR6; R6 = H, alkyl, etc.; or YR6 forms a 4- to 12-membered r. mo-N-contg. ring; Y, Y3, Z, Z3 = H, alkyl, aryl, cycloalkyl; or YZ or Y3Z3 form cycloalkyl; n = 1-3; t = 0-2; p = 0-3; R = XR3; X = O, S, NH, etc.; R3 = H, alkyl, etc.; R1 = H, alkyl, alkenyl, etc.; R11 = H, alkyl, aralkyl, etc.] are prep'd. For example, m-nitrohippuric acid was subjected to a sequence of (1) amidation with Et 3-amino-3-(3-pyridyl)propanoate-2HCl; (2) hydrogenation of the nitro group; (3) reaction of the formed amine with benzyl isocyanate; and (4) alk. sapon. of the ester, to give title compd. II, isolated as the CF3CO2H or HCl salt. In an in vitro assay for antagonism of human vitronectin receptor (.alpha.V.beta.3), the title compd. II.HCl bound with an IC50 of 0.86 nM.				
IT	188804-85-5P 188805-16-5P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of meta-guanidino, -ureido, -thioureido, or -azacyclic-amino benzoic acid derivs. as integrin antagonists)

RN 188804-85-5 CAPLUS


CN Benzoic acid, 2-[[2-[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-3-carboxypropyl]thio]-, (S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 188804-84-4

CMF C21 H23 N5 O6 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 188805-16-5 CAPLUS

CN Butanoic acid, 3-[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-(phenylthio)-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 188804-78-6P 188804-79-7P 188804-82-2P


188804-83-3P 188804-84-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of meta-guanidino, -ureido, -thioureido, or -azacyclic-amino benzoic acid derivs. as integrin antagonists)

RN 188804-78-6 CAPLUS

CN Butanoic acid, 3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-(phenylthio)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188804-79-7 CAPLUS


CN Butanoic acid, 3-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-4-(phenylthio)-, (S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 188804-78-6

CMF C20 H23 N5 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 188804-82-2 CAPLUS

CN Benzoic acid, 2-[[2-[[[[3-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]amino]-3-carboxypropyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188804-83-3 CAPLUS


CN Benzoic acid, 2-[(2-[(3-[(aminoiminomethyl)amino]benzoyl]amino)acetyl]amino]-3-carboxypropylsulfone-, (S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 188804-82-2

CMF C21 H23 N5 O8 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 188804-84-4 CAPLUS

CN Benzoic acid, 2-[(2-[(3-[(aminoiminomethyl)amino]benzoyl]amino)acetyl]amino)-3-carboxypropylthio)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

